methods, systems, devices and kits for sample analyte detection

专利摘要:
"METHODS AND SYSTEMS FOR SAMPLE ANALYT DETECTION. This description provides methods for detecting one or more analytes in a sample. Aspects of the methods include passing a sample (for example, a biological sample, such as blood) through a channel comprising a specific analyte capture domain stably associated with its surface, where the specific analyte capture domain comprises particles that have a specific analyte binding member, and view the specific analyte capture domain to detect whether the analyte is present in the sample, systems, devices and kits that can be used when practicing the methods under examination are also provided.The methods and compositions as described in this document are useful in a variety of different applications, including diagnostic applications.
公开号:BR112014010718B1
申请号:R112014010718-1
申请日:2012-11-16
公开日:2020-12-22
发明作者:Wei Huang；Scott Bornheimer
申请人:Becton, Dickinson And Company；
IPC主号:

专利说明:

CROSS REFERENCE TO RELATED ORDERS
[001] In accordance with 35 USC § 119 (e), this application claims priority to the filing date of U.S. provisional patent application serial number 61 / 560,752, filed on November 16, 2011, the description of which is here incorporated by reference. INTRODUCTION
[002] Point-of-care tests (POC) facilitate the diagnosis of diseases, particularly in situations where resources are limited and the health care infrastructure is weak, and access to prompt and timely medical treatment. quality is a challenge. POC tests often offer rapid results, allowing for rapid initiation of appropriate treatment. Significantly, POC tests can often be simple enough to be used at the level of primary health care and in remote situations with little or no laboratory structure. Therefore, POC tests offer advantages over other types of tests, such as microparticle immunoassays based on flow cytometry, which provide high accuracy and multiplexing, but are often not appropriate for POC situations due to costly sample preparation and expensive equipment.
[003] For example, POC tests facilitate the diagnosis or treatment of HIV / AIDS. In most countries with limited resources, eligibility for antiretroviral therapy for HIV / AIDS is based on a CD4 + T lymphocyte count. Traditional CD4 counting technologies require a venous blood sample to be processed by a laboratory. After a positive HIV test, patients provide a blood sample immediately or are referred to another center if the HIV sampling and counseling site does not accept blood samples. The blood sample is then sent to a laboratory for processing using, for example, tests based on flow cytometry. Depending on the capacity of the laboratory, results are typically available between 2 and 14 days after the patient has supplied the sample. Patients return to the clinic to receive the results, and can then be referred for future HIV treatment and / or care. However, about 40% of patients in such situations do not provide a blood sample or do not return to the clinic to obtain the results. POC tests can facilitate the diagnosis of HIV / AIDS by simplifying the blood collection process and making the results available while the patient is still in a clinical setting. In addition, POC tests can potentially allow such patients to do their own tests in the privacy of their homes, particularly in the case of stigmatic diseases such as HIV / AIDS.
[004] Most POC tests for infectious diseases offer a single diagnosis per test. Recently, multiplexed POC tests have been developed, as has the Multiplo® POC test (MedMira Inc, NS, Canada). POC multiplexed tests can, in principle, diagnose multiple infectious diseases, thus offering the promise of simultaneous detection of pathologies (for example, HIV, hepatitis B and C, syphilis, etc.) with greater convenience for patients and providers. At the moment, however, evidence of its performance in real world situations is limited. Rapid diagnosis of multiple infectious diseases from a single sample (for example, a single drop of finger-prick blood) using easy and inexpensive technology available at the bedside ("point-of-care") would significantly increase the effects global health. SUMMARY
[005] The present description provides methods for the detection of one or more analytes in a sample. Aspects of the methods include passing a sample (for example, a biological sample, such as blood or blood product) through a channel comprising a specific analyte capture domain stably associated with its surface, where the capture domain includes particles that present an analyte-specific binding member; and view the specific analyte capture domain to detect whether the analyte is present in the sample. Systems, devices and kits that can be used when practicing the methods under examination are also provided. The methods and compositions are useful in a variety of different applications, including diagnostic applications, environmental test applications, etc.
[006] The present description provides methods for detecting whether an analyte is present in a sample, wherein the methods include passing a sample through a capillary channel comprising a specific analyte capture domain stably associated with its internal surface at a known location, wherein the specific analyte capture domain includes particles that have an analyte specific binding member on such a surface; and view the specific analyte capture domain to detect whether the analyte is present in the sample. Particles of interest include, but are not limited to, spheres (e.g., capture spheres that have an analyte-specific binding member), antibodies and their antigen-binding fragments, nucleotide sequences and the like.
[007] The present description also provides methods for detecting whether a plurality of analytes is present in a sample, such as 2 or more analytes (for example, about 3 to 5 analytes, about 5 to 8 analytes, about 8 to 12 analytes, etc). For example, to detect a first and a second analyte, methods may include passing the sample through a capillary channel comprising specific capture domains for a first and second analyte stably associated with an internal surface thereof in known locations, where the first specific analyte capture includes particles that have a specific binding member of the first analyte on such a surface, and the second specific analyte capture domain includes particles that have a specific binding member of the second analyte on such a surface; and viewing the first and second specific analyte capture domains to detect whether the first and second analytes are present in the sample. The first and second binding member domains can be located at different locations within the capillary channel. Such methods can be adapted to detect whether a third, fourth, fifth, etc. analyte is present in a sample, for example, by adding a third, fourth, fifth, etc. specific analyte capture domain for that analyte.
[008] The modalities of this description allow the rapid detection of one or more analytes (for example, 2 or more, such as 3, 4, 5, etc.) in a sample. This detection can be qualitative and / or quantitative. A variety of analytes can be detected by methods of the present description, including analytes of biological and / or non-biological origin (for example, chemical and / or synthetic analytes). Analytes of interest include, but are not limited to, cells, antibodies, polypeptides, polynucleotides, etc. In some ways, an analyte is a biomarker. Thus, the methods of the present description can facilitate the detection, monitoring and / or diagnosis of one or more pathologies in a subject from a biological sample obtained from the subject. The method modalities are compatible with POC tests that detect multiple infectious diseases from a single biological sample (for example, a single drop of blood from a digital puncture) using low-cost technology.
[009] Aspects of the methods include generating a report indicating the probability of the subject having one or more pathology (s) based on the verification of the presence of an analyte in a sample obtained from a subject. The methods of the present description may include selecting a therapy for the subject based on the likelihood of the condition (s). The methods of the present description may include administering a therapy to the subject based on the likelihood of the condition (s). When the subject is receiving treatment, the methods of the present description may include modifying the subject's therapy based on the results of the trial (s).
[0010] The methods of this description can be used with a wide range of sample types, including samples containing organic and / or non-organic material. The organic material can be of biological or non-biological origin. Examples of biological samples of interest include, but are not limited to, blood (e.g., whole blood), saliva, urine, bile fluid, and the like. Such samples can be obtained from an in vitro source (for example, a cell suspension obtained from cultured laboratory cells) or from an in vivo source (for example, a mammalian subject, a human subject, etc.). In other respects, the samples contain only non-organic material, such as material that is chemical (for example, synthetic) of origin. In certain embodiments, a sample contains organic and non-organic material.
[0011] The method aspects of this description include the staining of an analyte. The marking of an analyte can be direct or indirect, as described in more detail in this document. In some respects, a sample is marked before the sample is passed through a capillary channel. The modalities also include, or as an alternative, the passage of a specific analyte marker through the capillary channel after the sample has been passed through the capillary channel. A wide variety of markers can be used when practicing the methods under examination, and markers of interest include, but are not limited to, indocarbocyanine (C3), indodicarbocyanine (C5), Cy3, Cy3.5, Cy5, Cy5.5, Cy7 , Texas Red, Pacific Blue, Oregon Green 488, Alexa fluor-355, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor-555, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 647, Alexa Fluor 660, Alexa Fluor 680, Alexa Fluor 700, JOE, Lissamine, Rhodamine Green, BODIPY, fluorescein isothiocyanate (FITC), carboxyfluorescein (FAM), phycoerythrin, rhodamine, dichlororodamine (dRhodamine), carboxy-tetramethyl rhodamine (TAMRA), carboxy-X-rod (X-rod) ROX), LIZ, VIC, NED, PET, SYBR, PicoGreen, RiboGreen, and the like.
[0012] The present description also provides devices to detect whether an analyte is present in a sample. The aspects of the devices include a capillary channel that includes a specific analyte capture domain stably associated with its internal surface at a known location, where the specific analyte capture domain includes particles (for example, capture spheres) that present a specific analyte binding member on such a surface. Methods of preparing the devices are also provided. For example, methods are provided for stably associating particles (e.g., capture spheres) that have an analyte-specific binding member with a channel surface (e.g., a plastic capillary channel).
[0013] The present description also provides systems for detecting whether an analyte is present in a sample. The system modalities aspects of the present description include a capillary channel that includes a specific analyte capture domain stably associated with its internal surface at a known location, where the specific analyte capture domain includes particles that have a member of specific binding of the analyte on such a surface; and an image generator configured to obtain an image of the specific analyte capture domain. The image generators of interest include, but are not limited to, microscopes (for example, a low power microscope), cameras (for example, a CCD camera), optical scanners and the like. The systems can include a processor, such as a processor contained in a processing module, configured to output a result in relation to the analyte being present in the sample based on the image obtained by the image generator.
[0014] The present description also provides kits, such as kits that include one or more specific analyte markers, and a device comprising a capillary channel that includes a specific analyte capture domain stably associated with its internal surface at a known location, in that the specific analyte capture domain includes particles that have a specific analyte binding member on such a surface (e.g., a device as described above).
[0015] These and other aspects will become apparent to people of ordinary skill in the art when examining the present description.
[0016] Since the early 1960s, immunoassay has become an essential biological analytical technology that is widely used in clinical diagnostics and life science research. Conventional immunoassay technologies, such as ELISA ("Enzyme-Linked ImmunoSorbent Assay"), combine the specificity of binding biomolecules as antibodies with the sensitivity of markers such as radioisotopes, enzymes and fluorescent markers and provide practical solutions for bioanalysis at a low cost. However, these assays typically require a liquid mass separation step (ie, washing) to remove unbound label molecules before final reading, and are not suitable for higher throughput applications that require a high level of automation, or applications at the bedside ("point-of-care") that require a simple and low-cost test procedure. Over the past three decades, many washless immunoassay technologies have been developed and marketed, including EMIT ("Enzyme Multiplied Immunoassay Technique"), CEDIA ("Clone Enzyme Donor Immunoassay"), LOCI ("Luminescence Oxygen Channeling Assay"), TR-FRET ("time resolved fluorescence resonance energy transfer") and fluorescence polarization. These technologies require complicated preparation of detection or instrumentation biomolecules and have limited application, particularly in bedside applications ("point-of-care").
[0017] To address the unmet need for immunoassays for point-of-care multiplexed applications suitable for the simultaneous detection of various diseases from a small sample volume, such as puncture whole blood digital, a new approach has been developed that combines multiplexed microparticle immunoassays with microfluidic assay design and low-cost digital imaging / visualization, preparing a simple production platform for the accurate measurement of infectious disease markers in whole blood without any preparation Sample. The washing step normally required in conventional ELISA assays is eliminated by specifically measuring the fluorescent label molecules attached to the microparticles, while reducing the interference of unbound label molecules in the test solution. Unlike conventional tests, where a combined optical signal is measured in a large volume of test solution without any spatial separation, digital visualization provides detailed two-dimensional information about the sample. With the visualization process and the computational analysis, the optical intensity of each microparticle can be measured in a specific way in two-dimensional space. Another aspect of our new approach described in this document is the defined ratio between height and particle size. Since the ratio of the channel height to the particle size is 50 or less, interference from the sample and unbound fluorescent markers in the third Z dimension is limited. In contrast to the assembly of a typical ELISA assay based on a microtiter plate, where a combined optical signal of the labeling molecules attached to the bottom of a microtiter plate is measured from the top of the plate, using several millimeters of assay containing unbound label molecules and other substances that could interfere, our new approach involves visualizing microparticles with a thin layer of assay fluid, thus allowing the assay to be carried out without needing a washing step. For example, in an embodiment of our invention, microparticles with a diameter of 7.5 μm are visualized inside a fluid channel with a height of 50 μm, thus dramatically reducing interference with the sample solution and eliminating the need mass separation (washing) of the test solution. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] The invention can be better understood from the following detailed description when read in conjunction with the accompanying drawings. The following figures are included in the drawings:
[0019] FIG. 1 provides a schematic illustration of certain modalities of the methods and devices of the present description.
[0020] In FIG. 2, panels A-B provide schematic illustrations of modalities of the present description. Panel A: A schematic illustration of certain modalities of the methods and devices of the present description, using HIV as an example. Panel B: A schematic illustration of experimental tests described in Examples.
[0021] In FIG. 3, panels A-B provide images showing the effects of the surface chemistry of the device on the ability of the spheres to adhere to the surface of a capillary channel after fluid has entered the cartridge. Panel A: BD TruCount ™ Beads adhere to the capillary channel of a plastic device where the surface of the device has been treated with oxygen plasma. Panel B: The spheres lose their adhesion to the cartridge surface that has not been treated with oxygen plasma, and are removed. The arrows indicate spheres of capture that have been moved due to the fluid passing through the capillary channel by capillary action.
[0022] In FIG. 4, panels A-C provide data obtained from the detection of mouse antibodies labeled in whole blood with immobilized BD CompBeads beads (coated with anti-mouse mouse antibody), using methods and devices of the present description. The error bars represent the standard deviation of 3 replicates (FOVs) in a single channel. Panels A-C show the detection of mouse antibodies labeled with APC, PE-Cy5 and PE, respectively.
[0023] FIG. 5 is an illustration of a cartridge type device according to an embodiment of the present description. DETAILED DESCRIPTION
[0024] The present description provides methods for the detection of one or more analytes in a sample. Aspects of the methods include passing a sample (e.g., a biological sample, such as blood or blood product) through a channel comprising a specific analyte capture domain stably associated with its surface, where the specific analyte capture domain includes particles that have an analyte-specific binding member; and view the specific analyte capture domain to detect whether the analyte is present in the sample. Systems, devices and kits that can be used when practicing the methods under examination are also provided.
[0025] Before the present invention is described in more detail, it should be understood that this invention is not restricted to the particular modalities described, as these may vary. It should also be understood that the terminology used in this document is only for the purpose of describing particular modalities, and the intention is not to be restrictive, since the scope of the present invention is limited only by the appended claims.
[0026] When a range of values is provided, it should be understood that each intermediate value, up to one tenth of the unit of the lower limit unless otherwise indicated, between the upper and lower limit of that range, and any other value quoted or intermediate in this indicated range, will be covered in the invention. The maximum and minimum limits of these minor bands can be independently included in the minor bands and are also covered in the invention, subject to any limit specifically excluded from the mentioned band. When the cited range includes one of the limits or both limits, the ranges that exclude one of the limits or both of the limits included are also included in the invention.
[0027] Unless otherwise stated, all technical and scientific terms used in this document have the same meaning as that generally understood by a person skilled in the art with respect to that invention. Although any methods and materials similar or equivalent to those described herein can also be used in carrying out or testing the present invention, representative methods and illustrative materials are described below.
[0028] All publications and patents cited in that specification are hereby incorporated by citation as if each individual publication or patent were specifically and individually indicated to be incorporated by citation and are incorporated into this document by citation for the purpose of disseminating and describing the methods and / or materials referring to the reason for citing publications. The citation of any publication is for its description before the filing date and should not be interpreted as an admission that the present invention is not entitled to precede the description by virtue of the foregoing invention. In addition, the publication dates provided may differ from the actual publication dates which may need to be independently confirmed.
[0029] It is noted that, as used here and in the appended claims, the singular forms of "one", "one", "o" and "a" include referents in the plural, unless the context explicitly indicates otherwise. It is also highlighted that claims can be formulated to exclude any optional elements. Accordingly, this statement is intended to serve as an antecedent basis for the use of such exclusive terminology as "only", "only" and the like with reference to the description of elements of the claims, or use of a "negative" limitation.
[0030] As will be apparent to those skilled in the art when reading this specification, each of the individual modalities described and illustrated in this document has discrete components and characteristics that can be easily isolated from or combined with the characteristics of any of the various other modalities without depart from the scope or spirit of the present invention. Any method described can be performed in the order of events described or in any other order that is logically possible. METHODS
[0031] As described above, the present description provides methods for detecting whether an analyte is present in a sample. Aspects of the methods include passing a sample (e.g., a biological sample, such as blood or blood product) through a channel comprising a specific analyte capture domain stably associated with its surface, where the specific analyte capture domain includes particles that have an analyte-specific binding member; and view the specific analyte capture domain to detect whether the analyte is present in the sample.
[0032] The modalities of the methods include the detection of more than one analyte from a single sample, that is, the detection of multiplex analytes. Thus, the present description provides multiplex assays for identifying a plurality of analytes from a single sample. The methods under examination can be used to detect whether 2 or more analytes are present in a sample, including 3 or more, such as about 2 to 100 analytes, for example, 3 to 5 analytes, 5 to 8 analytes, 8 to 12 analytes, 12 to 15 analytes, 15 to 20 analytes, 20 to 30 analytes, 30 to 40 analytes, 40 to 50 analytes, 50 to 60 analytes, 60 to 70 analytes, 70 to 80 analytes, 80 to 90 analytes, or 90 to 100 analytes. As the detection of analytes in tests according to certain modalities has a special component, for example, the location of a capture domain on the surface of the capillary channel uniquely identifies the analyte to which the capture domain is directed, a sample can be traced to 100 or more analytes in some cases.
[0033] For example, to detect a first and second analyte, methods may include passing the sample through a capillary channel that includes specific capture domains for a first and second analyte stably associated with (for example, immobilized on) an internal surface this at known sites, where the first specific analyte capture domain includes particles that have a specific binding member of the first analyte on such a surface, and the second specific analyte capture domain includes particles that have a specific binding of the second analyte on such a surface; and viewing the first and second specific analyte capture domains to detect whether the first and second analytes are present in the sample. The first and second binding member domains can be located at different locations within the capillary channel. Such methods can be adapted to detect whether a third, fourth, fifth, etc. analyte is present in a sample, for example, by adding a third, fourth, fifth, etc. specific analyte capture domain for that analyte.
[0034] In some embodiments, methods for detecting whether one or more target analyte (s) are present in a sample can be performed in 3 hours or less, including 60 minutes or less, such as 30 minutes or less, 20 minutes or less, 10 minutes or less, 5 minutes or less, or 1 minute or less. Thus, aspects of the methods can be used in POC tests.
[0035] In some cases, the tests are "no wash" tests. By testing without washing it is understood that the protocol does not include any washing step between the capture step and the visualization step. Thus, after contacting the sample with a capture domain, the capture domain is not washed or otherwise treated to remove components from the sample before visualization. In other words, an image is obtained from the capture domain without first removing any components from the sample.
[0036] In some embodiments, the methods of the invention for detecting whether an analyte is present in a sample are qualitative, where the detection of the analyte is qualitative, for example, it is determined whether or not the analyte is present in the sample. In some embodiments, the methods of the invention for detecting whether an analyte is present in a sample are quantitative, where the detection of the analyte is quantitative. Methods may include determining a quantitative measure of the number of analyte particles (eg, antibodies) present in a sample. In some embodiments, quantifying the number of analyte particles present in a sample includes determining whether the number of analyte particles is above or below a predetermined threshold value.
[0037] FIG. 1, provides a schematic illustration of modalities of the present description. In this embodiment, a sample 10 is introduced into a capillary channel 12. Channel 12 contains a region comprising reagents 14. Reagents in that region can be preserved and / or dried. Sample 10 flows over that region 14, mixing with any reagents that may be present. The sample then flows (for example, by capillary action) over one or more specific analyte capture domains. In the illustration shown in FIG. 1, the example provides a first specific analyte capture domain 15 to detect a first analyte, a second specific analyte capture domain 16 to detect a second analyte, a third specific analyte capture domain 17 to detect a third analyte, and a fourth specific analyte capture domain 18 to detect a fourth analyte. Each of the specific analyte capture domains 15 to 18 can be visualized to detect whether the respective analyte is present in sample 10. In some cases, visualization protocols (as implemented by devices and / or algorithms) can be used to obtain measurements independent of each sphere (from the same test) that are statistically combined to provide an overall result. Thus, FIG. 1 illustrates a multiplexed assay.
[0038] In FIG. 2, Panel A provides a schematic illustration of modalities of the present description. In this non-limiting example 200, a sample 20 (for example, whole blood) is placed in a capillary channel 22 of a cartridge device (for example, as described in more detail below; see, for example, FIG. 5) , with a width w (for example, w = 3mm, 5mm, etc.). Channel 22 is designed so that conserved reagents 24 (for example, conserved anti-human allophychocyanine antibody (APC)) are suspended by introducing sample 20, mixed with sample 20, and then passed to the capture domains 25 and 26. The highest magnification image shows a side view in greater magnification of channel 12 and capture domain 26. Channel 12 has a height h, where h is equal to a height that is 50 times, or less, greater than than the average diameter of the particles contained in the capture domain 26. This capture domain 26 contains particles located on the upper surface of the channel, for example, on the surface closest to the imager. The particles have a binding member 28 (for example, gp41 antigen) that binds to the target analyte 30 (for example, anti-gp41 antibody) present in sample 20. A marker 32 (for example, the anti-human-allophicocyanin antibody) (Conserved APC) also binds, resulting in the formation of a complex (for example, particle / anti-gp41 antibody / APC-anti-human antibody complexes; see, for example, FIG. 2, Panel B). Visualization of the specific analyte capture domain (bottom image) can be performed using any convenient protocol (for example, using an LED, such as a red LED). In certain aspects, visualization is performed without separating the sample particles. Visualization can be performed from the top of channel 22. In visualization, fluorescence can be measured using any convenient protocol to provide a qualitative or quantitative measurement, for example, by measuring fluorescence by visualization from the top of the cartridge using a microscope low power with a CCD camera detector and an appropriate filter. The intensity of fluorescence in the particles can be quantified after image processing and analysis. In the case of multiplexed assays, particles coated with different disease-associated antigens can be fixed at specific locations in the capillary channel. Thus, the same marker can be used for all capture domains, simplifying the visualization protocol, since the location of the image can be used to determine the identity of the analyte. Alternatively, two or more capture domains can be present in overlapping locations or at the same location on the channel, for example, when different markers are used for each analyte or when alternative criteria for identifying spheres, such as size or intensity in a channel for additional detection, are used to enable spheres from multiple assays in overlapping locations.
[0039] Several steps and aspects of the methods will be described in more detail below. ANALYTES
[0040] As described above, the present description provides methods for detecting whether an analyte is present in a sample. The term "analyte" is used in this document in a broad and generic way to refer to a compound or composition of interest that will be detected.
[0041] A variety of analytes can be detected by methods of the present description, including analytes of biological and / or non-biological origin (for example, chemical and / or synthetic analytes). Examples of analytes of interest include, but are not limited to, cells, drugs, hormones, polypeptides, proteins (eg, antibodies), polysaccharides, nucleic acids, chemicals, heavy metals, pathogens (eg, bacteria, prions, fungi, viruses , etc.), and their combinations.
[0042] In certain aspects, the analyte is a biomarker. A "biomarker" as used in this document generally refers to an organic biomolecule (for example, an antibody) that is differentially present in a sample obtained from a subject with phenotypic status (for example, who has a disease) compared to another phenotypic status (for example, who does not have the disease or who has a different disease). A biomarker is differentially present in different phenotypic states if the average or median level of the biomarker in a first phenotypic state in relation to a second phenotypic state is calculated to represent statistically different differences. Common tests for statistical significance include, among others, the t test, ANOVA, Kruskal-Wallis, Wilcoxon, Mann-Whitney and the ratio of possibilities. Biomarkers, alone or in combination, provide measures of the relative probability of a subject belonging to a phenotypic state of interest. Thus, biomarkers can be used as markers for, for example, diseases (diagnosis), the therapeutic efficiency of a drug (teranosis) and the like. Biomarkers are, therefore, analyzed in assays that facilitate diagnosis, teranosis and the like.
[0043] The biomarkers of interest appropriate for the identification of one or more conditions (for example, infectious diseases) include, but are not limited to, those described, for example, in the infectious disease biomarker database (Infectious Disease Biomarker Database) . This tool is accessible on the website found by placing "www." in front of "biomarker.korea.ac.kr/index.jsp". The database of infectious disease biomarkers is described in Yang, et al. (2008) Nucleic Acid Res. 36: D455-D460; whose description is incorporated by reference. Appropriate biomarkers, as well as specific binding members suitable for use in the practice of the methods under examination, are further described in, for example, S Aidoo, et al. (2001) J. Clin. Microbiol. 39: 2572-2575 for HIV; HS Shin, et al. (2001) Clin. Diagn. Lab. Immunol. 8: 9-13 for hepatitis B; R Allwinn, et al. (1999) Infection 27: 365-367 for dengue; And Araz, et al. (2000) Trans. R. Soc. Trop. Med. Hyg. 94: 55-56 for malaria; B Berdal, et al. (2000) Scand. J. Infect. Dis. 32: 287-291 for tularemia; S Chanteau, et al. (2000) Int. J. Med. Microbiol. 290: 279-283 for bubonic plague; W Ching, et al. (2001) Clin. Diagn. Lab. Immunol. 8: 409-414 for typhus; J Dominguez, et al. (1999) Eur. J. Clin. Microbiol. Infect. Dis. 18: 896-98 for Legionellosis; WH Schrier, et al. (1998) Clin. Chem. 44: 293- 298 for infection by H. pylori; whose descriptions are hereby incorporated by reference. SAMPLES
[0044] Analyte (s) can be detected in a sample. The term "sample" as used herein means any fluid containing one or more individual analytes in suspension at any desired concentration. For example, the sample may contain 1011 or less, 1010 or less, 109 or less, 108 or less, 107 or less, 106 or less, 105 or less, 104 or less, 103 or less, 500 or less, 100 or less , 10 or less, or one analyte per milliliter. The sample may contain a known number of analyte molecules or an unknown number of analyte molecules.
[0045] When practicing the methods of this description, the sample can be a biological sample. A "biological sample" encompasses a variety of sample types obtained from a subject. The definition encompasses biological fluids (eg blood (including blood fractions (eg serum, plasma)); and other liquid samples of biological origin (eg saliva, urine, bile fluid)). "Blood sample" refers to a biological sample, which is obtained from the blood of a subject, and includes samples of whole blood and blood fractions (for example, plasma or serum) suitable for analysis using the methods under examination. In general, the separation of cellular components and acellular components in a blood sample (for example, by centrifugation) without coagulation provides a blood plasma sample, while such clotting of blood provides a blood serum sample. Examples of biological blood samples include peripheral blood or samples derived from peripheral blood. The definition also includes samples that were manipulated after being obtained, such as by treatment with reagents, solubilization or enrichment for certain components, such as one or more polypeptides to be analyzed. For example, a biological sample (for example, blood) can be enriched in a fraction containing an analyte (s) of interest.
[0046] Appropriate biological samples useful in the methods of the present description include biological fluids (for example, a blood sample, for example, whole blood, blood fraction (for example, serum, plasma)); and other liquid samples of biological origin. When the biological sample is a blood sample, the blood sample can be obtained from fresh blood or stored blood (for example, in a blood bank). The biological sample can be a blood sample that was expressly obtained for an assay of the present description or a blood sample obtained for another purpose, but that can be sub-sampled for an assay of the present description.
[0047] Samples can be manipulated after being obtained, such as by treatment with reagents, solubilization, and / or enrichment for certain components, for an analyte (s) to be analyzed. Samples can be pre-treated when necessary by dilution in an appropriate buffer solution, concentrated when desired, or fractionated by any method including, but not limited to, ultracentrifugation, fractionation by rapid performance liquid chromatography (FPLC), or precipitation.
[0048] Thus, in some modalities, the sample is obtained from an in vivo source. In certain embodiments, the source of the sample is a "mammal" or "mammal", where these terms are used widely to describe organisms that are within the mammalian class, including orders of carnivores (for example, dogs and cats), rodents (for example, mice, guinea pigs and rats) and primates (for example, humans, chimpanzees and monkeys). In some cases, the subjects are human beings. The methods can be applied to samples obtained from human subjects of both sexes and at any stage of development (ie, newborn, child, juvenile, adolescent, adult), where in certain modalities, the human subject is juvenile, adolescent or adult. While the present invention can be applied to samples from a human subject, it should be understood that the methods can also be performed on samples from other animal subjects (i.e., "non-human subjects") such as, but without limitation, birds, mice, rats, dogs, cats, cattle and horses.
[0049] When practicing the methods of this description, the sample can be a non-biological sample. For example, a sample may include a suspension of non-biological particles obtained, for example, from soil, food, water and the like. Non-biological samples of interest include samples for use in environmental testing, as will be described in more detail in this document.
[0050] The sample size may also vary. In certain embodiments, the sample includes 100 μl or less of fluid, such as 50 μl or less, including about 5 to 50 μl. A sample can be obtained, for example, by finger prick (for example, the sample includes a single drop of finger prick blood). In still other embodiments, the sample size may be larger, for example, 100 μl or more, such as 500 μl or more, including 1 ml or more, for example, 5 ml or more, such as when several milliliters of sample they are passed through a capture region to accumulate the analyte signal at very low concentration. Any convenient means of obtaining a sample can be used in the practice of the methods under examination. THE PASSAGE OF A SAMPLE
[0051] In modalities of the methods under examination, a sample is passed through a channel. The terms "pass" and "flow" refer to the movement of a sample in any direction, with or without the use of external means (for example, a pump, syringe and the like). Examples of flow, therefore, include mechanically promoted fluid passage, such as passage using a pump, such as a syringe pump, peristaltic pump or peristaltic pump. Examples of flow therefore also include fully passive flow, such as gravimetric fluid flow, capillary action and the like.
[0052] The term "capillary action" is used in this document to refer to the flow of fluid, vertical and / or lateral, without the use of external means. Capillary action can occur, for example, when a fluid is placed in a "capillary channel", which is a channel, path or conduit with properties that allow the movement of a fluid by capillary action.
[0053] For example, samples (for example, whole blood) can flow by capillary action in channels that have dimensions and / or other properties that allow the production of capillary action for this specific type of sample. Factors that have an impact on capillary flow include those described in, for example, S Chakraborty (2005) Lab Chip. 5 (4): 421-430. Thus, a sample can flow through a capillary channel when the fluid is introduced into the channel (for example, it comes into contact with the channel, is injected into the channel, etc.), where the capillary action causes the fluid to move through of the channel.
[0054] In certain modalities, the channel is a "micro" channel. Such channels can have at least a cross-sectional dimension of the order of a millimeter or less (for example, less than or equal to about 1 millimeter). This dimension can be adjusted; in some embodiments, at least one cross-sectional dimension is 500 micrometers or less. In some embodiments, again when permitted by applications, the cross-sectional dimension is 100 micrometers or less, such as 50 micrometers or less, including 1 micrometer or less.
[0055] A cross-sectional dimension is one that is generally perpendicular to the flow direction by the central line, although it should be understood that when elbow flow or other characteristics that tend to change the flow direction occur, the cutting dimension cross-section may not necessarily be perpendicular to the flow. It should also be understood that in some modalities, a microchannel may have two or more cross-sectional dimensions, such as the height and width of a rectangular cross-section or the major and minor axes of an elliptical cross-section. Any of these dimensions can be compared with the sizes shown in this document. Note that the microchannels used in carrying out the methods of the present description may have two dimensions that are quite disproportionate, for example, a rectangular cross section that has a height of 10 to 200, such as 20 to 100 micrometers and a width of the order of one mm or more, for example, 3 to 10 mm or more. For example, the channel illustrated in FIG. 2, Panel A, has a rectangular cross-section with a height of 50 micrometers and a width of 3 mm. Of course, certain devices may employ channels in which the two or more axes are very similar or even identical in size (for example, channels that have a square or circular cross-section).
[0056] In relation to the above, it should be understood that some of the design principles and characteristics described in this document, can be adjusted for larger devices and systems including devices and systems that employ channels that achieve channel cross-sections in the millimeter scale or even centimeters. Thus, when describing some devices and systems as "micro", it is understood that the description applies equally, in certain modalities, to some larger scale devices.
[0057] The dimensions of a channel can be changed for the particle size (s) used in the specific analyte capture domain (s). In some respects, the relative size of the particles and the height of the channel is such that the height and / or width of the channel is less than about 50 times the average diameter of the particles, such as about 25 to 50 times the average diameter of particles, including 5 to 10 times the average diameter of the particles, or 3 to 5 times the average diameter. For example, if the particles are spheres with an average diameter of about 7.5 μm, in certain embodiments, the height and / or width of a channel will be about 375 μm or less, including 75 μm or less, such as 37 , 5 μm or less (for example, 22.5 μm).
[0058] The cross-sectional dimensions of the channel can be changed for the particular type of sample used, with the height of the channel being such that the sample can separate into one or more layers. For example, when the sample is a biological sample (for example, blood), red blood cells in whole blood will precipitate at the bottom of the channel, leaving lighter plasma at the top. Plasma and red blood cells can therefore be passively separated when there is an appropriate height dimension (for example, about 375 μm or less, including about 37.5 μm or less, such as about 22.5 μm) . In such aspects, a specific analyte capture domain can be stably associated with a specific channel surface in order to preferentially interact with one or more of such layers. Using the blood example above, a specific analyte capture domain that is stably associated with the upper surface of a channel would preferably interact with analyte (s) present in the plasma, while a specific analyte capture domain that is stably associated with the bottom surface of a channel would preferentially interact with analyte (s) present in the fraction of red blood cells. Thus, by changing the dimensions of a channel and the location of a specific analyte capture domain (for example, on the upper surface of the channel), possible detection interference (for example, fluorescence detection) due to red blood cells is eliminated , allowing a simple assay for whole blood without separation.
[0059] The flow rate of a sample through a channel can vary. When the sample flows by passive flow only, such as gravimetric fluid flow, capillary action, and the like, the flow rate will be determined by several factors such as the type of sample (for example, viscosity), channel dimensions, and the like. In other respects, flow can be mechanically promoted (for example, using a pump, such as a syringe pump, peristaltic pump, or peristaltic pump) to achieve a desired flow rate (for example, 0.01 μl / minute or greater, 0.1 μl / minute or greater, 1 μl / minute or greater, 10 μl / minute or greater, 100 μl / minute or greater, 1 ml / minute or greater, or 100 ml / minute or greater).
[0060] The total time of fluid flow therefore depends on factors such as the flow rate and the length of the channel. In certain aspects, the total flow time is such that the sample has enough time to mix with one or more reagents that may be present in the channel. Referring again to FIG. 1, for example, sample 10 flows through capillary channel 12 by capillary action. Sample 10 passes over a region comprising reagents 14, and thereafter the sample continues to flow (by capillary action) over specific analyte capture domains 15-18. Thus, the distance between the reagent region 14 and the specific analyte capture domains 15-18 can vary depending on the desired time for the sample to mix with the reagent (s) present.
[0061] In certain aspects, a channel can be configured with a through-flow device. By "flow through" is meant that a sample can enter the channel through an input, be loaded through the channel, and exit the channel via an outlet. Aspects of the methods of the present description include taking the sample out of the channel. In certain respects, the sample collected can be further analyzed (for example, by one or more tests, such as tests based on flow cytometry and the like). CONNECTING MEMBERS
[0062] As described above, aspects of the methods include passing a sample through a channel comprising a specific analyte capture domain stably associated with one of its surfaces, wherein the specific analyte capture domain includes particles that have a member of specific binding of an analyte. The term "binding member" as used herein refers to any agent (e.g., a protein (e.g., an antibody), small molecule, and the like) that specifically bind to a target analyte. The terms "specific binding", "specifically binding", and the like, refer to the preferential binding of a molecule over other molecules or fractions in a solution or reaction mixture. In some embodiments, the affinity between the binding member and the target analyte to which it specifically binds, when specifically bound to each other in a binding complex, is characterized by a Kd (dissociation constant) of 10-6 M or less , such as 10-7 M or less, including 10-8 M or less, for example, 10-9 M or less, 10-10 M or less, 10-11 M or less, 10-12 M or less, 10 -13 M or less, 10-14 M or less, including 10-15 M or less. "Affinity" refers to the binding strength, with a higher binding affinity correlating with a lower Kd. Thus, "specifically bind" or "specifically bind" is not intended to exclude the binding of a given binding member with more than one analyte of interest. For example, antibodies that specifically bind to an analyte polypeptide of interest may be able to bind to other polypeptides at a low but detectable level (for example, 10% or less of the binding relative to the polypeptide of interest). Such weak binding, or background binding, can be easily differentiated from the specific binding of the antibody to the polypeptide of interest, for example, using appropriate controls.
[0063] In certain respects, the binding members may be antibodies, or their antigen binding fragments. As used herein, the term "antibodies" includes antibodies or immunoglobulins of any isotype, antibody fragments that retain specific antigen binding, including, but not limited to, Fab, Fv, scFv and Fd fragments, chimeric antibodies, humanized antibodies, single chain antibodies and fusion proteins comprising an antigen-binding portion of an antibody and a protein that is not an antibody. The antibodies can be additionally conjugated to other fractions, such as members of specific binding pairs, for example, biotin (member of the specific binding pair biotin-avidin), and the like. They are also encompassed by the term Fab ', Fv, F (ab') 2, and / or other antibody fragments that retain specific antigen binding, and monoclonal antibodies. In other respects, the binding members may be antigens, when the target analyte (s) are antibodies.
[0064] Aspects of modalities of the methods include the bonding of members that are contained within and / or in particles, such as capture spheres (eg, BD CompBeads, BD Biosciences, San Jose, CA). The particles can have a specific binding member (for example, an antigen) for one or more analytes.
[0065] The particles can be of a convenient size, and made of any convenient material (for example, polystyrene spheres, latex spheres, glass spheres, magnetic spheres, etc.). In certain respects, the relative size of the particles and the height of the channel are adjusted so that the height of the channel is 50 times, or less, the diameter of the particles, such as 5 to 10 times the diameter of the particles, including 3 to 5 times the diameter of the particles. The particles can also be natural particles, for example, cells or their derivatives.
[0066] The particles themselves may be located in one or more specific analyte capture domain (s) located within a channel. The specific analyte capture domain (s) can be located at any convenient location (s) on a channel. In some embodiments, the location (s) of the liaison member domains are known, while in other embodiments, the location (s) are unknown. In a given test, the particles can be the same or different sizes. For example, in some cases, the particles may have different sizes and / or be marked to increase the number of different analytes that can be detected in a given assay.
[0067] In some cases, the capture domain (s) are located in a region that maximizes the ratio between the signal and the background. In certain respects, the specific analyte capture domain (s) are located on the inner surface of the capillary channel that is closest to an imaging component, for example, a fluorescent light detector, during use. For example, when the imager is positioned near the upper outer surface of the channel (where the upper is relative to the source of gravity), the specific analyte capture domain (s) may be located on an upper surface of a channel. . The placement of specific analyte capture domain (s) on an upper surface of a channel can improve the accuracy of methods and / or simplify sample preparation, for example, by eliminating one or more separation steps. For example, when the sample is a biological sample (for example, blood), red blood cells in whole blood will precipitate at the bottom of the channel, leaving lighter plasma at the top (where the top is determined with respect to gravity). By placing specific analyte capture domain (s) on the upper surface of the channel and obtaining images from the top of the channel, the possible interference in the detection (eg fluorescence detection) due to red blood cells is eliminated, allowing a simple test for whole blood without separation.
[0068] The particles can be located within the specific analyte capture domain (s) by any appropriate means, such as by covalent and / or non-covalent bonding between the particles and the channel. For example, the stable association of particles with the channel is achieved by methods such as adsorption, absorption, evaporative deposition from a solution of volatile solvent, covalent bond between the particles and the channel, or immunological immobilization. Covalent bonding may, for example, involve bonding particles to the channel through a coupling agent, such as a cyanogen halide, for example, cyanogen bromide, or through the use of glutaraldehyde, as described in the U.S. patent. No. 4,186,146; whose description is incorporated by reference. Immunological immobilization in the channel can be by absorption, or by direct, covalent bonding, or through a linker of the type known to those skilled in the art. The methods for performing these procedures are provided, for example, by Iman and Hornby in Biochemical Journal (Volume 129; Page 255); Campbell, Hornby, and Morris at Biochem. Biophys. Acta (1975), Volume 384; Page 307; Mattisson and Nilsson in F.E.B.S. Letters, (1977) Volume 104, Page 78; and in US patent numbers 4,376,110 and 4,452,901; whose descriptions are incorporated herein by reference.
[0069] Methods of interest for stably associating particles of a specific analyte capture domain with a surface include, but are not limited to, the methods described in DR Thevenot, et al. Biosens. Bioelectron. 16, 121-131 (2001); AF Collings, et al .. Rep. Prog. Phys. 60, 1397-1445 (1997); YG Li, et al .. Anal. Chim. Acta 382, 277-282 (1999); MA Breimer, et al. Biosens. Bioelectron. 18, 1135-1147 (2003); XD Dong, et al. Biolectrochem. Bioenerg. 42, 63-69 (1997); JT Andersen, et al. Bioelectrochem. Bioenerg. 44, 57-63 (1997); FS Ligler, et al. Anal. Chem. 74, 713-719 (2002); M. Manning, et al. Mater. Sci. Eng. C 23, 347-351 (2003); OA. Sadik, et al. Anal. Chem. 74, 3142-3150 (2002); Akkoyun, et al. Biosens. Bioelectron. 17 (8), 655-664 (2002); S Cosnier. Biosens. Bioelectron. 14, 443-456 (1999); S. Cosnier, et al. Electrochim. Acta 44 (11), 1833-1836 (1999); Ouerghi, et al. J. Electroanal. Chem. 501, 62-69 (2001); J Wang, et al. Electrochem. Commun. 5, 83-86 (2003); F Yan, et al. Anal. Chem. 73, 5272-5280 (2001); B Hock, et al. Biosens. Bioelectron. 17, 239-249 (2002); whose descriptions are incorporated herein by reference.
[0070] In certain aspects, the particles are located within the specific analyte capture domain (s) by means of totally passive (ie, non-covalent) interactions between the particles and the channel surface. Such interactions can be strong enough to keep particles attached to the channel surface even after fluid passes through the channel (see, for example, FIG. 3, Panel A). For example, the inner surface may be an inner surface marked by plasma and the particles may be stably associated with it, for example, as described in the experimental section below, and elsewhere.
[0071] One or more specific analyte capture domains comprising binding members for a target analyte may be present in a channel. For example, in certain aspects, a specific analyte capture domain is present for a target analyte. In other respects, two or more (e.g., 2 to 10, about 10 to 20, etc.) specific analyte capture domains comprising binding members for a target analyte are present. When two or more specific analyte capture domains are present for a target analyte, the specific analyte capture domains can be homogeneous or heterogeneous (that is, differ in terms of the binding member for the targeted analyte, the type of particle used , the particle size used, etc.).
[0072] When methods are used to detect whether two or more target analytes are present in a sample, one or more specific analyte capture domain (s) may be present for each target analyte. The specific analyte capture domains for different target analytes can be located at different locations within the channel to allow multiplexed detection of the different target analytes. For example, a first analyte capture domain specific to a first analyte may be located in a different location than a second analyte capture domain specific to a second analyte, so that the visualization of each specific analyte capture domain is able to detect whether the first or second analyte is present in the sample. Likewise, a third, fourth, fifth, etc. specific analyte capture domain can be positioned to allow detection of a third, fourth, fifth, etc. analyte in the sample. See, for example, FIG. 1.
[0073] In certain respects, the particles of the first, second, etc. analyte are also, or alternatively, located in overlapping specific analyte capture domains (including the same). In such aspects, the particles may have binding members that can be differentially marked for the first, second, etc. analyte. In this way, the particles can be stably associated with the same locations or overlapping locations, and yet be differentiated from particles of a different antigen (for example, differentiated by their fluorescent emissions).
[0074] When desired, a quality control domain may also be present, for example, a domain that has particles associated with known characteristics that provide a signal during visualization that can be used as a control or reference for the test results. MARKERS
[0075] In some modalities, the methods involve using a marker to detect whether a target analyte is present in a sample. As used herein, the terms "marker" and "detectable marker" refer to a molecule capable of being detected, including, but not limited to, radioactive isotopes, fluorescent agents, chemiluminescent agents, chromophores, enzymes, enzyme substrates, cofactors enzymes, enzyme inhibitors, chromophores, dyes, metal ions, metal suns, binders (for example, biotin, avidin, streptavidin or haptens), intercalating dyes and the like. The term "fluorescent agent" refers to a substance or portion thereof that is capable of showing fluorescence within the detectable range.
[0076] Markers of interest include both direct and indirect detection markers. The markers can be linked directly to an analyte and / or to an analyte / binding member complex (see, for example, FIG. 2, Panels A and B). In FIG. 2, Panel B shows a possible binding scheme, in which particles 26 with binding members 28 (e.g., mouse anti-Ab) bind to a detection reagent with a labeled Ab 32.
[0077] In certain respects, a sample is marked before the sample is passed through a capillary channel. The modalities also include, or as an alternative, the passage of a specific analyte marker through the capillary channel after the sample has been passed through the capillary channel.
[0078] In certain aspects, a marker can be included in the channel and mix with the sample as the sample flows through the channel. For example, using the example illustrated in FIG. 1, as sample 10 passes through capillary channel 12 by capillary action, sample 10 passes over a region comprising reagents 14, and after that the sample continues to flow (by capillary action) over domains of capture of specific analyte 15-18. The region comprising the reagents 14 may, in some respects, include one or more markers which are mixed with the sample as it flows through the channel.
[0079] Markers appropriate for use in the methods described in this document include any molecule that can be indirectly or directly detected by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical, chemical or other means. Markers of interest include, but are not limited to, fluorescein and its derivatives; rhodamine and its derivatives; cyanine and its derivatives; coumarin and its derivatives; Cascade Blue and its derivatives; Lucifer Yellow and its derivatives; BODIPY and its derivatives; and the like. Markers of interest also include fluorophores, such as indocarbocyanine (C3), indodicarbocyanine (C5), Cy3, Cy3.5, Cy5, Cy5.5, Cy7, Texas Red, Pacific Blue, Oregon Green 488, Alexa fluor-355, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor-555, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 647, Alexa Fluor 660, Alexa Fluor 680, Alexa Fluor 700, JOE, Lissamine, Rhodamine Green, BODIPY, isothiocyanate fluorescein (FITC), carboxyfluorescein (FAM), phycoerythrin, rhodamine, dichlororodamine (dRhodamine), carboxytetramethyl rhodamine (TAMRA), carboxy-X-rhodamine (ROX), LIZ, VIC, NED, PET, SYBR, PicoGreen, RiboGreen, and similar.
[0080] The fluorescent markers can be detected using a photodetector to detect the emitted light. Appropriate detectors include, but are not limited to, the detectors described in U.S. Patent Nos. 7,927,561 and 7,738,094; whose descriptions are incorporated herein by reference. Enzymatic markers are typically detected by supplying a substrate to the enzyme and detecting the reaction product produced by the action of the enzyme on the substrate, colorimetric markers can be detected by simply viewing the color marker, and antigenic markers can be detected by providing an antibody (or a binding fragment thereof) that specifically binds to the antigenic marker. An antibody that specifically binds to an antigenic marker can be directly or indirectly detected. For example, the antibody can be conjugated to a marker fraction (for example, a fluorophore) that provides the signal (for example, fluorescence); the antibody can be conjugated to an enzyme (for example, peroxidase, alkaline phosphatase, etc.) that produces a detectable product (for example, a fluorescent product) when an appropriate substrate is provided (for example, fluorescent tiramide, FastRed, etc.); etc.
[0081] When the methods are multiplexed, one or more analytes can be marked with different markers. In certain respects, the markers are selected so that they are differentiated from each other, for example, when the emission spectra of a first marker and a second marker do not substantially overlap. VISUALIZATION
[0082] As described above, the modalities of the methods include the visualization of the specific analyte capture domain (s) to detect whether the target analyte is present in the sample.
[0083] Visualization of the specific analyte capture domain can be performed using any convenient protocol. The term "visualization" is used broadly to refer to any way of evaluating a region to verify the presence or absence of a signal from a capture domain, where the signal is produced by the marker if the marker is present in the domain capture. That is, when a capture domain is visualized, it is evaluated using any convenient protocol to detect whether a marker is present in the domain. In some aspects, visualization may involve the use of an optical scanner or microscope, such as a low-powered microscope with a CCD camera detector and an appropriate filter. In certain aspects, visualization may involve the use of a dedicated visualization device configured for use in the methods of the present description (for example, Alere Pima, BD CD4 at the bedside, and the like).
[0084] Visualization may involve the use of image processing. Any convenient image processing protocol can be employed in the methods of the present description. For example, visualization may involve processing 2D images. Such processing may, for example, involve distinguishing between particles and the background by size and / or intensity in order to quantify the intensity (e.g., the fluorescence intensity) of the particles contained in a specific binding member domain.
[0085] In certain respects, one or more of the steps above can be performed using commercially available image viewing software, such as the Pipeline Pilot (Accelrys) image processing toolbox, ImageJ, Matlab, Perkin Elmer Velocity, Media Cybernetics ImagePro Plus, Metamorph, and / or Nikon Elements. In other respects, one or more steps in the process are performed by custom software modules. REPORTS
[0086] The methods under examination can be used to detect one or more biomarkers in a biological sample obtained from a subject. The detection of the biomarker (s) can indicate whether the subject has, or is at risk of, having one or more pathologies (for example, HIV, hepatitis B and C, syphilis, malaria, etc.).
[0087] The methods of this description may include generating a report indicating the results of the method and providing guidance on how the results can be applied in terms of the care of a subject. A "report" as described in this document, generally refers to an electronic document or file (for example, a pdf file, displayed on the screen), as well as a tangible document (for example, a paper report). A subject's report can be fully or partially generated electronically, for example, presented on an electronic viewfinder (for example, a computer monitor).
[0088] The results of the method in the report may include, for example, one or more of the quantities of the target analyte (s) analyzed. The level can be reported as a quantitative value (for example, a concentration, for example, pg / ml of serum) and / or a semi-quantitative value (for example, a value that reflects the amount of an analyte in relation to a level of control or a specific baseline level). The results of the method may optionally include the results of testing a control analyte.
[0089] Reports may include guidance to a clinician on a recommended treatment for the subject based on the subject's likelihood of having one or more pathology (s). For example, reports may include a recommendation on further evaluation and / or whether to avoid expensive and invasive evaluations and / or recommendations on therapeutic intervention (eg, administration of a drug, recommendation for surgical intervention, etc.), modifying a treatment regimen (eg, adjusting the dose of a drug (eg, increasing or decreasing the dose)), adjusting the dosage regimen (eg, increasing or decreasing the frequency and / or quantity of the dose) and the like.
[0090] A report may additionally include one or more of: 1) information about the patient (for example, name, medical information (for example, age, sex, symptoms (for example, symptoms that may be relevant to the diagnosis of (s) pathology (s)), etc.), 2) information about the biological sample (for example, the type, when it was obtained); 3) information on where and how the test was carried out (for example, the diagnostic center, test format); 4) information about the service provider; and / or 5) an interpretative report, which can provide a narrative with an at least partial interpretation of the results in order to facilitate diagnosis by a physician.
[0091] Thus, the methods described in this document may also include a step of generating or producing a report that provides the results of the method and, optionally, other information such as guidance on treatment, as described in this document. The report can be provided by electronic means (for example, an electronic viewfinder on a computer monitor), or by tangible means (for example, a report printed on paper or other tangible means). A probability assessment can be called a "risk report" or, simply, a "diagnostic result". The person or entity preparing a report ("report generator") can also perform steps such as collecting the sample, processing the sample, and the like. Alternatively, an entity other than the report generator can perform steps such as sample collection, sample processing, and the like. A report can be provided to a user. A "user" can be, for example, a healthcare professional (for example, a clinician, a lab technician, a doctor, etc.). DEVICES AND SYSTEMS
[0092] The present description also provides devices and systems for detecting whether an analyte is present in a sample.
[0093] The aspects of the devices include a capillary channel that includes a specific analyte capture domain stably associated with its internal surface at a known location, where the specific analyte capture domain includes particles (for example, capture spheres ) that have a specific analyte binding member on such a surface.
[0094] As described above, passing a sample through a channel may involve the use of a "micro" channel that has at least a cross-sectional dimension of the order of a millimeter or less (for example, 1 millimeter or less) , where in some embodiments the cross-sectional dimension is 100 micrometers or less (including 50 micrometers or less - such as 1 micrometer or less). Thus, in some embodiments, the devices of the present description are manufactured using microfabrication technology.
[0095] The devices can be made of any convenient material, with a channel comprising glass, plastic and the like. The devices can be configured to be disposable and / or manufactured at low cost, and can facilitate long-term storage (for example, storage does not require a cold chain).
[0096] In certain respects, the devices are configured so that conserved reagents are located in one or more separate locations from the particles, and the fluid system is configured so that the introduction of the sample resuspends the reagents, mixes with them, and then it moves to a detection zone containing the particles. General methods of preparing such devices include those described in, for example, U.S. Patent No. 8,025,850; whose description is incorporated herein by reference.
[0097] The devices of interest include cartridge devices and / or cartridge type devices. A non-limiting example of such a device is shown in FIG. 5. That device 300 includes a body 102, which includes a cover 101. The cover 101 can be attached to the body 102 and / or connected to it by a hinge, so that the cover 101 is opened or moved to expose a region of sample loading 111. The sample can be loaded in the sample loading region 111, with the sample flowing into channel (for example, a capillary channel) 112 within body 102. Channel 112 can be straight, curved and the like . In FIG. 5, for example, channel 112 includes straight and curved portions. Channel 112 can include a region comprising reagents 114. Reagents in that region can be conserved and / or dried. The sample flows over that region 114, mixing with any reagents that may be present. The sample then flows (for example, by capillary action) over one or more specific analyte capture domains, such as the specific analyte capture domain 115. The specific analyte capture domain 115 can then be visualized to detect whether the target analyte is present in a sample, such as measuring fluorescence by visualization from the top of cartridge 300 using a low-power microscope with a CCD camera detector and an appropriate filter.
[0098] In device 300, the sample loading region 111 may include a skin puncture element (e.g., a needle and / or prick puncture element) to puncture a subject's skin to produce a sample (e.g. example, blood). In such embodiments, the sample loading region 111 thus allows the sample to be taken from the subject and loaded directly into device 300 without any further sample preparation.
[0099] The body 102 of the device 300 can be made of any (any) convenient material (s), such as plastic, glass and the like. In certain aspects, body 102 is transparent and / or made of a material that allows visualization of the specific analyte capture domain (s) present in channel 112 through body 102. Body 102 and cover 101 can be configured to be substantially resistant to dust, dirt, water, moisture, temperature and the like.
[00100] The dimensions of such devices may vary. In certain respects, the length of the device may be * page 30, paragraph 100 6 inches or less, such as 5 inches, 4 inches, 3 inches, 2 inches or 1 inch. The width of the device can vary, in some ways ranging from 1 inch or less (for example, about 0.5 inches to 1.0 inch) to 3 inches or more. In some ways, the width is 0.1 to 0.5 inches, 0.5 to 1.0 inches, 1.0 to 1.5 inches, 1.5 to 2.0 inches, 2.0 to 2, 5 inches, 2.5 to 3.0 inches, or 3.0 to 5.0 inches. The depth (i.e. thickness) of the device can also vary, in some ways ranging from 0.1 to 1 inch or more, including about 0.1 to 0.5 inches, 0.5 to 1.0 inches, or 1.0 to 1.5 inches.
[00101] The format of device 300 and / or body 102 can be configured to be inserted in an image generator, such as an entrance or receptacle in an image generator. Thus, the shape and / or dimensions of a device can be determined by the shape and / or dimensions of the entrance or receptacle in such an image generator, or the shape and / or dimensions of the entrance or receptacle in such an image generator can be determined by the shape and / or dimensions of a device. Inserting the device into an input or receptacle of an image generator can facilitate the visualization of one or more specific analyte capture domains present in the device, without the image generator circuit being directly exposed to the sample contained in the device (for example , a blood sample).
[00102] The present description also provides systems for detecting whether an analyte is present in a sample. The system modalities aspects of the present description include a capillary channel that includes a specific analyte capture domain stably associated with its internal surface at a known location, where the specific analyte capture domain includes particles that have a member of specific binding of the analyte on such a surface; and an image generator configured to obtain an image of the specific analyte capture domain. The image generators of interest include, but are not limited to, microscopes (for example, a low power microscope), cameras (for example, a CCD camera), optical scanners and the like.
[00103] The methods of the present description can be implemented on a computer, so that method steps (for example, analysis, visualization and the like) are fully or partially automated. Thus, the systems of the present description can include a processing system, which generally includes at least one processor or processing unit or plurality of processors, memory, at least one input device and at least one output device, coupled by means of a bus or group of buses. In certain embodiments, an input device and an output device can be the same device. Memory can be any form of memory device, for example, volatile or non-volatile memory, solid state storage devices, magnetic devices, etc. The processor may comprise more than one distinct processing device, for example, to perform different functions within the processing system.
[00104] The systems of this description can include several additional components, such as data output devices, for example, monitors, printers and / or speakers, data input devices, for example, inputs for interfaces, mouse, keyboard , etc., fluid handling components, energy sources, etc. KITS
[00105] Kits are also provided for carrying out one or more modalities of the methods described above. The kits under examination may include various components and reagents, for example, capillary channel devices (such as cartridge devices); reagents for sample preparation, including sample labeling reagents, etc., as described above.
[00106] In some respects, the kits include one or more specific analyte markers, and a device comprising a capillary channel that includes a specific analyte capture domain stably associated with its internal surface at a known location, where the domain Specific analyte capture methods include particles that have a specific analyte binding member on such a surface (for example, a device as described above).
[00107] In some cases, the kits include at least reagents that are useful in the methods (for example, as described above); and a computer reading medium with a stored computer program, in which the computer program, when loaded on a computer, causes the computer to perform an assay as described in this document to detect whether an analyte is present in a sample; and a physical substrate that has an address from which the computer program can be obtained.
[00108] In addition to the above components, the kits under examination may also include instructions for carrying out the methods. These instructions may be present in a variety of forms in the kits under examination, one or more of which may be present in the kit. One way in which these instructions can be present is as information printed on an appropriate medium or substrate, for example, piece or pieces of paper on which the information is printed, on the kit packaging, on an insert in the packaging, etc. Still other means would be computational reading means, for example, CD, DVD, Blu-Ray, flash memory, etc., in which the information was recorded. Yet another means that can be present is a website address that can be used on the internet to access information on a removed website. Any convenient means may be present in the kits. UTILITY
[00109] The methods, devices, systems and kits under examination are useful in a variety of different applications where it would be desirable to detect whether an analyte is present in a sample. DIAGNOSTIC TEST APPLICATIONS
[00110] For example, the methods, devices, systems and / or kits of the present description can be used to facilitate the diagnosis of a pathology in a subject using a biological sample obtained from the subject. Such methods, devices, systems and / or kits can be multiplexed, allowing for rapid diagnosis of various pathologies (for example, various infectious diseases) from a single sample, such as a single drop of finger-prick blood. The present description therefore facilitates detection at the bedside ("point-of-care") of one or more biomarkers in a biological sample, thus being more convenient for patients and suppliers, and improving the overall health effects.
[00111] Examples of pathologies of interest include, but are not limited to, infectious diseases and / or infections (eg viral infections) such as HIV / AIDS, dengue fever, West Nile fever, malaria, Rift Valley fever, ebola, smallpox, yellow fever, syphilis and hepatitis B. One or more pathologies, for example, one or more of the pathologies listed above, can be detected and diagnosed in a subject, as several specific binding members are known, including specific binding members described in, for example, S Aidoo, et al. (2001) J. Clin. Microbiol. 39: 2572-2575 for HIV; HS Shin, et al. (2001) Clin. Diagn. Lab. Immunol. 8: 9-13 for hepatitis B; R Allwinn, et al. (1999) Infection 27: 365-367 for dengue; And Araz, et al. (2000) Trans. R. Soc. Trop. Med. Hyg. 94: 55-56 for malaria; B Berdal, et al. (2000) Scand. J. Infect. Dis. 32: 287-291 for tularemia; S Chanteau, et al. (2000) Int. J. Med. Microbiol. 290: 279-283 for bubonic plague; W Ching, et al. (2001) Clin. Diagn. Lab. Immunol. 8: 409-414 for typhus; J Dominguez, et al. (1999) Eur. J. Clin. Microbiol. Infect. Dis. 18: 896-898 for Legionellosis; WH Schrier, et al. (1998) Clin. Chem. 44: 293-298 for infection by H. pylori; whose descriptions are hereby incorporated by reference.
[00112] For example, in certain aspects, the appropriate binding members may be antigens that are specifically linked by antibodies (i.e., the target analytes) against antigens found on the viral capsid. For example, the methods, devices, systems and / or kits of the present description can be used in the diagnosis of HIV / AIDS, in which the particles contained in one or more specific analyte capture domains have a binding member (for example, gp41 antigen) that specifically binds to the target analyte (eg, anti-gp41 antibody) to facilitate the diagnosis of HIV / AIDS.
[00113] Thus, the methods, devices, systems and / or kits of the present description can provide results that can then be applied to facilitate the decisions made regarding the care of a subject. Other examples are provided below. TESTED GUIDED THERAPY AND THERAPY MONITORING
[00114] The methods of the present description can help a clinician to make a decision about the treatment of the subject, for example, if the results of the method suggest that the subject may or may not benefit from antiretroviral therapy for HIV / AIDS. Symptoms, clinical signs and other factors, such as family history can also be considered to facilitate the selection of a therapy.
[00115] The results of the method can guide a clinician on whether or not a therapy should be administered for the treatment of a pathology.
[00116] The methods of the present description can facilitate the monitoring of the therapy of a subject who is receiving treatment for a pathology. For example, when the subject is already receiving therapy, the method may provide a method of monitoring the therapy. In this case, the results of the method can guide a clinician about adjusting the therapy (for example, whether the therapy should be continued or not (for example, to prevent a relapse), increase or decrease the dose, change the therapy regimen ( for example, from monotherapy to combination therapy, or from non-surgical therapy to surgical therapy) when the patient is not receiving adequate therapeutic benefits (for example, the patient is not responding to therapy) and the like). Such methods of monitoring therapy are useful to guide treatment decisions, for example, if continued administration of a drug regimen is indicated. The methods of monitoring therapy using the methods of the present description can be used in combination with other methods to assess whether a subject is responding to therapy (whether it is a "responder") or whether it is not showing a sufficient therapeutic beneficial response (if it is a "non-responder"). IDENTIFICATION OF SUBJECTS FOR POPULATIONS OF CLINICAL STUDIES
[00117] The methods of the present description are useful for the identification of subjects suitable for inclusion or exclusion from a clinical study based on the probability of the subject having, or being at risk of having, one or more pathologies. For example, the methods of the present description can be used to identify subjects suitable for inclusion in a clinical study (for example, because they have one or more pathologies). In another example, the methods of the present description can be used to identify subjects who have one or more pathologies so that they are excluded from a clinical study (for example, when the clinical study is to evaluate the efficacy of a drug in relation to a first pathology in subjects who do not have a second pathology). The methods and devices described in this document can also be used in testing new biomarkers in a clinical study setting, as the POC format decreases the work required of healthcare professionals and reduces the risk of errors, and reduces the complexity of procedures in the thus increasing participation. In addition, by performing multiplexed tests on the same sample drop (for example, finger prick), several relevant clinical results for monitoring or classifying patients can be obtained regarding the new biomarkers under investigation. ENVIRONMENTAL TEST APPLICATIONS
[00118] The methods, devices, systems and / or kits of the present description can also be used in various environmental testing applications, where they can be used to detect analytes such as pesticides, polychlorinated biphenyls (PCBs), heavy metals, chemical endocrine disrupters ( EDCs), pathogens (for example, pathogenic bacteria), and the like.
[00119] For example, polychlorinated biphenyls (compounds involved in the production of immunological abnormalities, reproductive dysfunction and increased thyroid volume) can be detected using methods, devices, systems and / or kits of the present description in which an anti-PCB antibody is used as the specific liaison member. Suitable anti-PCB antibodies are described in, for example, S Bender, et al. Environ. Sci. Technol. 32, 788-797 (1998) and M Masila, et al. Biotechnol. Bioprocess Eng. 5, 407-412 (2000); whose descriptions are incorporated herein by reference.
[00120] Similarly, one or more chemical endocrine disrupters (EDCs), which structurally resemble endogenous estrogens, can be detected in a sample. EDCs are chemicals that can interfere with the body's endocrine system and have adverse effects on the development, reproduction, neurological and immune systems of human and non-human animals. Specific binding members suitable for use in the detection of EDCs such as alkylphenol ethyls, bisphenol A and linear sulfonated alkylbenzenes are known and described in, for example, T Matsunaga, et al. Anal. Chim. Acta 475, 75-83 (2003); whose description is incorporated herein by reference.
[00121] The methods, devices, systems and / or kits of the present description can also be used in the detection of pathogens, such as pathogenic bacteria that can be found in soil, food, and staurine and marine waters. Specific binding members suitable for various pathogens, such as Bacilus globigii, MS2 bacteriophage, and Staphlyococcal enterotoxin, are known and described in, for example, CA Rowe, et al. Anal. Chem. 71, 3846-3852 (1999); whose description is incorporated herein by reference. EXEMPLIFICATIVE MODALITIES
[00122] Exemplary non-limiting modalities of the present description are provided as follows:
[00123] A method for detecting whether an analyte is present in a sample, where the method comprises:
[00124] passing the sample through a capillary channel comprising a specific analyte capture domain stably associated with its internal surface at a known location, wherein the specific analyte capture domain comprises particles that have a specific analyte binding member on such a surface, and where the capillary channel has a height less than 50 times greater than an average particle diameter; and
[00125] visualize the specific analyte capture domain to detect if the analyte is present in the sample, in which the visualization is performed without the separation of the sample particles.
[00126] The method according to quantitative.
[00127] The method according to semiquantitative.
[00128] The method according to 1, where detection is 1, where detection is 1, where detection is qualitative.
[00129] The method according to any one from 1 to 4, in which the capillary channel has a height less than a height 40 times greater than an average particle diameter.
[00130] The method according to any one from 1 to 5, in which the capillary channel has a height less than a height 30 times greater than an average diameter of the particles.
[00131] The method according to any of 1 to 6, in which the capillary channel has a height less than a height 20 times greater than an average diameter of the particles.
[00132] The method according to any one from 1 to 7, in which the capillary channel has a height less than a height 10 times greater than an average diameter of the particles.
[00133] The method according to any one from 1 to 8, in which the capillary channel has a height less than a height 5 times greater than an average diameter of the particles.
[00134] The method according to any one from 1 to 9, in which the capillary channel has a height less than a height 3 times greater than an average diameter of the particles.
[00135] The method according to any one from 1 to 10, comprising marking the sample before the sample is passed through the capillary channel.
[00136] The method according to 11, wherein the marker comprises a fluorescent marker.
[00137] The method according to any one from 1 to 12, comprising the passage of a specific analyte marker through the capillary channel after the sample has been passed through the capillary channel.
[00138] The method according to 13, wherein the specific analyte marker comprises a fluorescent marker.
[00139] The method according to 13 or 14, wherein the specific analyte marker comprises an antibody or antigen-binding fragment thereof.
[00140] The method according to any one from 1 to 15, in which the particles are capture spheres.
[00141] The method according to 16, in which the capture spheres are coated with a binding reagent that specifically binds to the analyte.
[00142] The method according to any of 1 to 17, in which the sample is a biological sample.
[00143] The method according to any one from 1 to 18, in which the biological sample is from a human being.
[00144] The method according to 18 or 19, in which the biological sample is blood or a blood product.
[00145] The method according to 20, in which the blood product is serum or plasma.
[00146] The method according to any one from 18 to 21, comprising obtaining the biological sample from the subject.
[00147] The method according to any one from 1 to 22, in which the analyte is an antibody or an antigen-binding fragment thereof.
[00148] The method according to any one from 1 to 23, comprising the generation of a report that indicates the probability of a pathology based on the detection of the presence of an analyte in a sample.
[00149] The method according to 24, in which the pathology is selected from the group consisting of HIV, malaria, syphilis, dengue and diabetes.
[00150] The method according to 24 or 25, in which the referred generation of a report is done by a computer.
[00151] The method according to 26, in which the report is displayed on an output device in a remote location relative to the computer.
[00152] The method according to any one of the 1 to 27, in which the visualization comprises the detection of a fluorescent emission to detect if the analyte is present in the sample.
[00153] The method according to any one from 1 to 28, in which the visualization is performed from an upper surface of the channel.
[00154] The method according to any of 1 to 29, in which the visualization is performed from a lateral surface of the channel.
[00155] The method according to any of 1 to 30, in which the visualization is performed from a position below the channel.
[00156] The method according to any one from 1 to 31, in which the visualization comprises processing of 2D images.
[00157] A method for detecting whether a first and second analyte are present in a sample, where the method comprises:
[00158] passing the sample through a capillary channel comprising a first and second specific analyte capture domain stably associated with an internal surface thereof at known locations, wherein the first specific analyte capture domain comprises particles that have a binding member specificity of the first analyte on such a surface, and where the second specific analyte capture domain comprises particles that have a specific binding member of the second analyte on such a surface, where the capillary channel has a height less than a height 50 times larger than an average particle diameter; and
[00159] visualize the first and second specific analyte capture domains to detect if the first and second analyte are present in the sample.
[00160] The method according to 33, in which the visualization is performed without separating the particles from the sample.
[00161] The method according to 33 or 34, in which the detection is quantitative.
[00162] The method according to 33 or 34, in which the detection is semi-quantitative.
[00163] The method according to 33 or 34, in which the detection is qualitative.
[00164] The method according to any of 33 to 37, in which the capillary channel has a height less than a height 40 times greater than an average diameter of the particles.
[00165] The method according to any one of 33 to 38, in which the capillary channel has a height less than a height 30 times greater than an average diameter of the particles.
[00166] The method according to any of 33 to 39, in which the capillary channel has a height less than a height 20 times greater than an average diameter of the particles.
[00167] The method according to any of 33 to 40, in which the capillary channel has a height less than a height 10 times greater than an average diameter of the particles.
[00168] The method according to any one of 33 to 41, in which the capillary channel has a height less than a height 5 times greater than an average diameter of the particles.
[00169] The method according to any one of 33 to 42, in which the capillary channel has a height less than a height 3 times greater than an average diameter of the particles.
[00170] The method according to any of 33 to 43, in which the first and second domains of capture of specific analyte are located in different positions in the capillary channel.
[00171] The method according to any one of 33 to 44, also comprising detecting whether a third analyte is present in the sample, in which the capillary channel comprises a third specific analyte capture domain stably associated with its internal surface in a known location, where the third specific analyte capture domain comprises particles that have a specific binding member of the third analyte on such a surface, and view the third specific analyte capture domain to detect whether the third analyte is present in the sample .
[00172] The method according to any of 33 to 45, comprising marking the sample before the sample is passed through the capillary channel.
[00173] The method according to 46, wherein the marker comprises a fluorescent marker.
[00174] The method according to any of 33 to 47, comprising the passage of a specific analyte marker through the capillary channel after the sample has been passed through the capillary channel.
[00175] The method according to 48, in which the specific analyte marker is specific for the first or second analyte.
[00176] The method according to 48 or 49, wherein the specific analyte marker comprises a fluorescent marker.
[00177] The method according to either 48 or 50, wherein the specific analyte marker comprises an antibody or antigen-binding fragment thereof.
[00178] The method according to any of 33 to 51, in which the particles are spheres of capture.
[00179] The method according to 52, in which the capture spheres are coated with a binding reagent that specifically binds to the first or second analyte.
[00180] The method according to any of 33 to 53, in which the sample is a biological sample.
[00181] The method according to any of 33 to 54, in which the biological sample is from a human being.
[00182] The method according to 54 or 55, in which the biological sample is blood or a blood product.
[00183] The method according to 56, in which the blood product is serum or plasma.
[00184] The method according to any of 54 to 57, comprising obtaining the biological sample from the subject.
[00185] The method according to any of 33 to 58, wherein the first analyte is an antibody or antigen-binding fragment thereof.
[00186] The method according to any of 33 to 59, wherein the second analyte is an antibody or antigen-binding fragment thereof.
[00187] The method according to any of 33 to 60, comprising the generation of a report that indicates the probability of a pathology based on the detection of the presence of the first analyte in the sample.
[00188] The method according to 61, in which the pathology is selected from the group consisting of HIV, malaria, syphilis, dengue and diabetes.
[00189] The method according to 61 or 62, comprising the generation of a report that indicates the probability of a second pathology based on the detection of the presence of the second analyte in the sample.
[00190] The method according to 63, in which the second pathology is selected from the group consisting of HIV, malaria, syphilis, dengue and diabetes.
[00191] The method according to any one of 61 to 64, in which the referred generation of a report is made by a computer.
[00192] The method according to 65, in which the report is displayed on an output device in a remote location relative to the computer.
[00193] The method according to any one of 33 to 66, wherein the visualization comprises the detection of a fluorescent emission to detect whether the first and second analytes are present in the sample.
[00194] The method according to any of 33 to 67, in which the visualization is performed from an upper surface of the channel.
[00195] The method according to any of 33 to 68, in which the visualization is performed from a lateral surface of the channel.
[00196] The method according to any of 33 to 69, in which the visualization is performed under the channel.
[00197] The method according to any of 33 to 70, in which the visualization comprises processing of 2D images.
[00198] A system for detecting whether an analyte is present in a sample, where the system comprises:
[00199] a capillary channel comprising a specific analyte capture domain stably associated with its internal surface at a known location, wherein the specific analyte capture domain comprises particles that have a specific analyte binding member on a surface of these, and in which the capillary channel has a height less than 50 times greater than an average particle diameter; and
[00200] an image generator configured to obtain an image of the specific analyte capture domain.
[00201] The system according to 72, in which the system additionally comprises a processing module configured to emit a result in relation to the analyte being present in the sample based on the image obtained by the image generator.
[00202] The system according to 72 or 73, in which the capillary channel comprises a second specific analyte capture domain stably associated with its internal surface in a known location, in which the second specific analyte capture domain comprises particles which have a specific binding member of a second analyte on such a surface, and where the imager is configured to obtain an image of the second specific analyte capture domain.
[00203] The system according to 74, in which the system additionally comprises a processing module configured to emit a result in relation to the second analyte being present in the sample based on the image obtained by the image generator.
[00204] The system according to any of 72 to 75, in which the capillary channel is removable.
[00205] The system according to any of 72 to 76, in which the image generator is an optical scanner or microscope.
[00206] The system according to any one of 72 to 77, comprising a counter configured to quantify an amount of analyte from the specific analyte capture domain.
[00207] A device for detecting whether an analyte is present in a sample, where the device comprises:
[00208] a capillary channel comprising a specific analyte capture domain stably associated with its internal surface at a known location, wherein the specific analyte capture domain comprises particles that have a specific analyte binding member on a surface of these, and in which the capillary channel has a height less than 50 times greater than an average particle diameter.
[00209] The device according to 79, in which the capillary channel has a height less than a height 40 times greater than an average particle diameter.
[00210] The device according to any of 79 to 80, in which the capillary channel has a height less than 30 times greater than an average particle diameter.
[00211] The device according to any one of 79 to 81, in which the capillary channel has a height less than a height 20 times greater than an average diameter of the particles.
[00212] The device according to any one of 79 to 82, in which the capillary channel has a height less than a height 10 times greater than an average diameter of the particles.
[00213] The device according to any of 79 to 83, in which the capillary channel has a height less than a height 5 times greater than an average diameter of the particles.
[00214] The device according to any one of 79 to 84, in which the capillary channel has a height less than a height 3 times greater than an average diameter of the particles.
[00215] The device according to any one of 79 to 85, in which the particles are capture spheres.
[00216] The device according to any of 79 to 86, in which the capillary channel is plastic.
[00217] A method for stably associating capture spheres presenting a specific binding member of an analyte with an internal surface of a capillary channel, in which the method comprises: treating the surface of the capillary channel with oxygen plasma to produce a plasma-marked surface; and depositing the capture spheres on the plasma-marked surface.
[00218] A kit comprising:
[00219] a capillary channel comprising a specific analyte capture domain stably associated with its internal surface at a known location, wherein the specific analyte capture domain comprises particles that have a specific analyte binding member on a surface of these, and in which the capillary channel has a height less than 50 times greater than an average particle diameter; and
[00220] a specific analyte marker. EXAMPLES
[00221] As can be seen from the description above, the present description has a wide variety of applications. Consequently, the following examples are presented to provide a full disclosure and description to one skilled in the art of how to make and use the present invention, and are not intended to be limiting with respect to the scope of what the inventors consider their invention, and are not intended to represent that the following experiments are all or the only experiments to be carried out. Those skilled in the art will quickly recognize a variety of non-critical parameters that could be altered or modified to obtain essentially similar results. Consequently, the following examples are presented to provide a complete description and description to one skilled in the art of how to make and use the present invention, and are not intended to be limiting with respect to the scope of what the inventors consider their invention, and are not intended to represent that the following experiments are all or the only experiments to be carried out. Efforts have been made to ensure the accuracy of the numbers used (for example, quantities, dimensions, etc.), but some deviations and experimental errors are possible. EXAMPLE 1: STABLE ASSOCIATION OF CAPTURE BALLS WITH A PLASTIC CAPILLARY CHAMBER
[00222] Capture spheres coated with anti-mouse antibodies (BD CompBeads, BD Biosciences, San Jose, CA) have been stably associated with the surface of a custom molded cycloolefin polymer capillary chamber. To evaluate the impact of the properties of the spheres, properties of the buffers and the surface chemistry of the capillary chamber on the ability of the spheres to adhere to the surface after passing fluids through the cartridge, a series of tests were carried out.
[00223] The impact of surface chemistry on the ability of the spheres to adhere to a plastic surface under the conditions in question was assessed by fixing BD TruCount ™ spheres on plastic surfaces and passing human plasma across the surface. The spheres were visualized using a personalized digital image generator system. The effect of the spheres' properties on the ability of the capture spheres to adhere to a plastic surface of a capillary chamber is illustrated in FIG. 3, Panel B.
[00224] The effect of capillary chamber chemistry on the ability of the capture spheres to adhere to a plastic surface of a capillary chamber is illustrated in FIG. 3, Panel B. In contrast, a cartridge surface treated with oxygen plasma allows beads to adhere to the cartridge surface (FIG. 3, Panel A). EXAMPLE 2: DETECTION OF ANALYTICAL IN A SAMPLE
[00225] A schematic overview of the experiments below is presented in FIG. 2, Panels A-B. Capture spheres (BD CompBeads, BD Biosciences, San Jose, CA) were stably associated with the upper surface of a capillary chamber, as described above in example 1. The spheres were coated with anti-mouse antibodies so that the spheres could capture any mouse antibodies in the sample. The spheres were marked with anti-human antibody made in mice immobilized in a location on the upper surface of the capillary chamber. The spheres remained in place due to inherent, presumably passive, interactions between the spheres and the plastic surface of the chamber.
[00226] The capillary channel was designed so that the height of the channel was less than 10 times the diameter of the capture spheres, with the ideal performance being observed when the height of the channel was about 3 to 5 times the diameter of the capture spheres.
[00227] In these dimensions, the relatively low height of the channel reduced the background fluorescent signal and allowed better measurement of the fluorescent signal of the capture spheres using a CCD camera, such as a CCD camera incorporated in a display device as described in the patents of the USA numbers 7,927,561 and 7,738,094; whose descriptions are incorporated herein by reference. The capillary channel was made of plastic.
[00228] Three differently labeled mouse antibody populations, labeled with APC, PE-Cy5 and PE, respectively, were added to a human whole blood sample. 20 μL of human whole blood was then introduced into the capillary channel. The sample was allowed to flow through the capillary by capillary action to the location of the immobilized capture spheres, allowing the capture of the marked antibodies.
[00229] The fluorescence of the labeled and captured antibodies was then measured using a low-power microscope. Filters were used to separate the light from the three dyes used, thus allowing isolated measurements of fluorescence. The results, shown in FIG. 4, Panels A-C, show that the fluorescence readings for each of the dyes were easily detectable using a low-power microscope.
[00230] Although the above invention has been described in some detail using illustrations and examples for the purpose of a clearer understanding, it will be readily apparent to those skilled in the art that in light of the teachings of this description, certain changes and modifications can be made to it without departing from the spirit or scope of the attached claims.
[00231] Consequently, the above only illustrates the principles of the invention. It will be appreciated that those skilled in the art may create various provisions which, although not explicitly described or shown in this document, incorporate the principles of the invention and are included in its spirit and scope. In addition, all examples and conditional language used in this document are intended to assist the reader in understanding the principles of the invention and are not limiting to the specific examples and conditions reported. In addition, all statements relating to principles, aspects and modalities of the invention in this document, as well as specific examples thereof, are intended to encompass their structural and functional equivalents. Additionally, it is intended that such equivalents include equivalents known at the time and equivalents that will be developed in the future, that is, any elements developed that perform the same function, regardless of the structure. Therefore, the scope of the present invention is not intended to be limited to the exemplary modalities presented and described in this document. Instead, the scope and spirit of the present invention are embodied in the appended claims.

权利要求:
Claims (18)
[0001]
1. Method for detecting whether an analyte is present in a sample, the method characterized by the fact that it comprises: passing the sample through a capillary channel that comprises a first specific analyte capture domain stably associated with its internal surface, where the first specific analyte capture domain comprises particles that have a specific analyte binding member on such a surface; and visualizing the first specific analyte capture domain to detect whether the analyte is present in the sample, where visualization is performed without separating the sample particles by washing.
[0002]
2. Method, according to claim 1, characterized by the fact that the detection is quantitative.
[0003]
3. Method, according to claim 1, characterized by the fact that the detection is qualitative.
[0004]
4. Method according to claim 1, characterized by the fact that the capillary channel has a height that is 50 times greater, or less, than an average particle diameter.
[0005]
5. Method, according to claim 1, characterized by the fact that it comprises the marking of the sample before the sample is passed through the capillary channel.
[0006]
6. Method according to claim 1, characterized by the fact that the particles are spheres.
[0007]
7. Method according to claim 1, characterized by the fact that the particles are cells.
[0008]
8. Method, according to claim 1, characterized by the fact that the sample is a biological sample.
[0009]
9. Method, according to claim 1, characterized by the fact that the biological sample is from a human being.
[0010]
10. Method, according to claim 1, characterized by the fact that it additionally comprises the generation of a diagnostic report based on whether the analyte is present in the sample.
[0011]
11. Method, according to claim 1, characterized by the fact that the particles are associated with an internal surface of the capillary channel and the visualization is performed from a side closer to the internal surface of the capillary channel.
[0012]
12. Method, according to claim 1, characterized by the fact that the capillary channel comprises a second specific analyte capture domain stably associated with its internal surface, in which the second specific analyte capture domain comprises particles that present a specific binding member of a second analyte on such a surface; and wherein the method further comprises visualizing the second specific analyte capture domain to detect whether the second analyte is present in the sample.
[0013]
13. Method according to claim 12, characterized by the fact that the first and second specific analyte capture domains are located at different positions in the capillary channel.
[0014]
14. System for detecting whether an analyte is present in a sample, the system characterized by the fact that it comprises: a capillary channel that comprises a specific analyte capture domain stably associated with its internal surface, in which the capture domain specific analyte comprises particles that have a specific analyte binding member on such a surface; and an image generator configured to obtain an image of the specific analyte capture domain.
[0015]
15. System, according to claim 14, characterized by the fact that the system additionally comprises a processing module configured to emit a result in relation to the analyte being present in the sample based on the image obtained by the image generator.
[0016]
16. Device to detect whether an analyte is present in a sample, the device characterized by the fact that it comprises: a capillary channel that comprises a specific analyte capture domain stably associated with an internal surface of that, in which the capture domain specific analyte comprises capture spheres that have a specific analyte binding member on such a surface.
[0017]
17. Method for stably associating capture spheres with a specific binding member of an analyte with an internal surface of a capillary channel, the method characterized by the fact that it comprises: treating the surface of the capillary channel with oxygen plasma to produce a plasma-marked surface; and depositing the capture spheres on the plasma-marked surface in an appropriate manner to stably associate the capture spheres with the internal surface of the capillary channel.
[0018]
18. Kit characterized by the fact that it comprises: a capillary channel comprising a specific analyte capture domain stably associated with its internal surface, where the specific analyte capture domain comprises particles that have a specific analyte binding member on such a surface; and a specific analyte marker.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112014010718B1|2020-12-22|methods, systems, devices and kits for sample analyte detection

---

CN105051538B|2018-06-15|For detecting the system and method for biological condition

---

JP2015522801A|2015-08-06|Clinical diagnostic system

---

CN105682763B|2019-01-29|Equipment, system and method for Capillary Electrophoresis

---

Cummins et al.2016|Point-of-care diagnostics for niche applications

---

JP2018513983A|2018-05-31|Test apparatus and method of use for detecting an analyte in a saliva sample

---

BR112015021199B1|2022-01-11|METHOD FOR DETERMINING WHETHER AN INFECTION IS BACTERIAL AND/OR VIRAL, AND SIDE FLOW DEVICE FOR DETECTION OF AN ANALYTE IN A SAMPLE

---

WO2019196270A1|2019-10-17|Micro-nano particles detection system and method thereof

---

Heinze et al.2010|Microfluidic immunosensor with integrated liquid core waveguides for sensitive Mie scattering detection of avian influenza antigens in a real biological matrix

---

CN108780061A|2018-11-09|System and method for the analysis of Capillary Electrophoresis, isoelectric point and molecular weight

---

Chung et al.2015|Nanoparticle detection of urinary markers for point-of-care diagnosis of kidney injury

---

US20180104685A1|2018-04-19|Microfluidic devices and methods for pathogen detection in liquid samples

---

Lin et al.2016|based CRP monitoring devices

---

Tsai et al.2019|Development of a multiplex and sensitive lateral flow immunoassay for the diagnosis of periprosthetic joint infection

---

Tan et al.2021|Cross-reactivity of SARS-CoV-2 with HIV chemiluminescent assay leading to false-positive results

---

US20190041407A1|2019-02-07|Devices, systems and methods for quantifying hemoglobin s concentration

---

US20180059103A1|2018-03-01|Devices and methods for detection of biomarkers

---

Li et al.2018|Microfluidic chip for cancer cell detection and diagnosis

---

Yang et al.2020|An immunoassay cassette with a handheld reader for HIV urine testing in point-of-care diagnostics

---

Li et al.2007|CD4+ T lymphocytes enumeration by an easy‐to‐use single platform image cytometer for HIV monitoring in resource‐constrained settings

---

KR20170087169A|2017-07-28|Counting analysis of Biomolecules, the Kit and Apparatus, and Their Use

---

CN212904935U|2021-04-06|Device and test strip for immunochromatography detection

---

CN212904930U|2021-04-06|Equipment and test strip for immunochromatography detection

---

KR20130060957A|2013-06-10|Apparatus and method for osteoporosis measurements and urine analysis apparatus

---

Lima et al.2021|Lab on a Paper‐Based Device for Coronavirus Biosensing

同族专利:

---

公开号 | 公开日

---

ZA201401130B|2016-03-30|

---

EP2780705A1|2014-09-24|

---

CN103917870A|2014-07-09|

---

EP2780705A4|2015-09-02|

---

EP3441142A1|2019-02-13|

---

CN103917870B|2016-04-13|

---

US20140170642A1|2014-06-19|

---

EP2780705B1|2018-09-19|

---

BR112014010718A2|2017-05-02|

---

WO2013075031A1|2013-05-23|

---

US9523682B2|2016-12-20|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US4125828A|1972-08-04|1978-11-14|Med-El Inc.|Method and apparatus for automated classification and analysis of cells|

---

US3819913A|1973-05-21|1974-06-25|Corning Glass Works|Detection of eosinophil cells on a blood smeared slide|

---

US3916205A|1973-05-31|1975-10-28|Block Engineering|Differential counting of leukocytes and other cells|

---

JPS5424680B2|1973-11-13|1979-08-22|

---

DE2523209A1|1975-05-26|1976-12-16|Noeller Hans Guenter Dr Med|ELECTRO-OPTIC, SUBSTANCE-CARE DETECTION OF NON-CELL-BONDED IMMUNE SUBSTANCES|

---

SE399768B|1975-09-29|1978-02-27|Lilja Jan E|CYVETT FOR SAMPLING, MIXING OF, THE SAMPLE WITH A REAGENTS AND DIRECT PERFORMANCE OF, SPECIAL OPTICAL, ANALYSIS OF THE SAMPLE MIXED WITH THE REAGENTS|

---

US4186146A|1979-02-01|1980-01-29|Suntech, Inc.|Hydrogenation of aromatic nitriles to primary amines|

---

JPH0133782B2|1980-01-07|1989-07-14|Fuji Photo Film Co Ltd|

---

US4452901A|1980-03-20|1984-06-05|Ciba-Geigy Corporation|Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays|

---

US4376110A|1980-08-04|1983-03-08|Hybritech, Incorporated|Immunometric assays using monoclonal antibodies|

---

US4501496A|1982-05-07|1985-02-26|Griffin Gladys B|Specimen slide for analysis of liquid specimens|

---

DE3238353A1|1982-10-15|1984-04-19|Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen|METHOD FOR SIMULTANEOUSLY QUANTITATIVE DETERMINATION OF BLOOD CELLS AND REAGENT THEREFOR|

---

US4727020A|1985-02-25|1988-02-23|Becton, Dickinson And Company|Method for analysis of subpopulations of blood cells|

---

US5134662A|1985-11-04|1992-07-28|Cell Analysis Systems, Inc.|Dual color camera microscope and methodology for cell staining and analysis|

---

US4959305A|1986-06-18|1990-09-25|Miles Inc.|Reversible immobilization of assay reagents in a multizone test device|

---

US6159740A|1987-03-13|2000-12-12|Coulter Corporation|Method and apparatus for screening obscured or partially obscured cells|

---

US4857735A|1987-10-23|1989-08-15|Noller Hans G|Light emitting diode spectrophotometer|

---

US5200152A|1988-03-28|1993-04-06|Cytonix Corporation|Miniaturized biological assembly|

---

US5073857A|1989-06-01|1991-12-17|Accuron Corporation|Method and apparatus for cell analysis|

---

US5053626A|1989-09-29|1991-10-01|Boston University|Dual wavelength spectrofluorometer|

---

US5102625A|1990-02-16|1992-04-07|Boc Health Care, Inc.|Apparatus for monitoring a chemical concentration|

---

JPH03291567A|1990-04-10|1991-12-20|Olympus Optical Co Ltd|Virus infection inspecting device and virus infection inspecting method|

---

US5159642A|1990-07-13|1992-10-27|Toa Medical Electronics Co., Ltd.|Particle image analyzing apparatus|

---

IE76732B1|1990-08-07|1997-11-05|Becton Dickinson Co|One step test for absolute counts|

---

US5348859A|1990-11-23|1994-09-20|Coulter Corporation|Method and apparatus for obtaining an absolute white blood cell subset count and white blood cell multipart differential|

---

US5196709A|1991-05-03|1993-03-23|University Of Maryland Systems|Fluorometry method and apparatus using a semiconductor laser diode as a light source|

---

US5385539A|1992-06-30|1995-01-31|Advanced Haemotechnologies|Apparatus for monitoring hematocrit levels of blood|

---

US5332905A|1992-08-26|1994-07-26|Atto Instruments, Inc.|Apparatus and method for multiple emission ratio photometry and multiple emission ratio imaging|

---

US6262798B1|1992-09-29|2001-07-17|Board Of Regents, The University Of Texas System|Method and apparatus for direct spectrophotometric measurements in unaltered whole blood|

---

US5733721A|1992-11-20|1998-03-31|The Board Of Regents Of The University Of Oklahoma|Cell analysis method using quantitative fluorescence image analysis|

---

US5294799A|1993-02-01|1994-03-15|Aslund Nils R D|Apparatus for quantitative imaging of multiple fluorophores|

---

US5556764A|1993-02-17|1996-09-17|Biometric Imaging, Inc.|Method and apparatus for cell counting and cell classification|

---

US5547849A|1993-02-17|1996-08-20|Biometric Imaging, Inc.|Apparatus and method for volumetric capillary cytometry|

---

US5489771A|1993-10-15|1996-02-06|University Of Virginia Patent Foundation|LED light standard for photo- and videomicroscopy|

---

US5491343A|1994-03-25|1996-02-13|Brooker; Gary|High-speed multiple wavelength illumination source, apparatus containing the same, and applications thereof to methods of irradiating luminescent samples and of quantitative luminescence ratio microscopy|

---

JP3146858B2|1994-06-30|2001-03-19|株式会社日立製作所|Optical detector for flow samples|

---

JP3529786B2|1994-07-14|2004-05-24|アボット・ラボラトリーズ|Cyanide-free assay method and reagents for hemoglobin and leukocytes in whole blood|

---

CA2156226C|1994-08-25|1999-02-23|Takayuki Taguchi|Biological fluid analyzing device and method|

---

US5599668A|1994-09-22|1997-02-04|Abbott Laboratories|Light scattering optical waveguide method for detecting specific binding events|

---

DE4438391C2|1994-10-27|1997-07-03|Evotec Biosystems Gmbh|Device for determining substance-specific parameters of one or fewer molecules by means of correlation spectroscopy|

---

US5658745A|1995-02-17|1997-08-19|E. I. Du Pont De Nemours And Company|Cell enumeration immunoassay|

---

US5692503A|1995-03-10|1997-12-02|Kuenstner; J. Todd|Method for noninvasive total hemoglobin, oxyhemogolobin, deoxyhemoglobin, carboxyhemoglobin and methemoglobin concentration determination|

---

US5528045A|1995-04-06|1996-06-18|Becton Dickinson And Company|Particle analyzer with spatially split wavelength filter|

---

US5682038A|1995-04-06|1997-10-28|Becton Dickinson And Company|Fluorescent-particle analyzer with timing alignment for analog pulse subtraction of fluorescent pulses arising from different excitation locations|

---

SE504193C2|1995-04-21|1996-12-02|Hemocue Ab|Capillary microcuvette|

---

US5675155A|1995-04-26|1997-10-07|Beckman Instruments, Inc.|Multicapillary fluorescent detection system|

---

JP3304692B2|1995-05-23|2002-07-22|株式会社島津製作所|Spectrometer|

---

US5732150A|1995-09-19|1998-03-24|Ihc Health Services, Inc.|Method and system for multiple wavelength microscopy image analysis|

---

US6215892B1|1995-11-30|2001-04-10|Chromavision Medical Systems, Inc.|Method and apparatus for automated image analysis of biological specimens|

---

AU1288497A|1995-12-18|1997-07-14|Center For Laboratory Technology, Inc.|Multi-parameter hematology apparatus and method|

---

AT403412B|1996-04-02|1998-02-25|Avl Verbrennungskraft Messtech|DEVICE AND METHOD FOR DETERMINING THE CONCENTRATION OF HEMOGLOBIN DERIVATIVES IN AN UNDILINED, UNHEMOLYZED WHOLE BLOOD SAMPLE|

---

JP3788519B2|1996-06-28|2006-06-21|カリパー・ライフ・サイエンシズ・インコーポレーテッド|High-throughput screening assay system for microscale fluid devices|

---

AT404513B|1996-07-12|1998-12-28|Avl Verbrennungskraft Messtech|METHOD AND MEASURING ARRANGEMENT FOR THE OPTICAL DETERMINATION OF TOTAL HEMOGLOBIN CONCENTRATION|

---

US6396941B1|1996-08-23|2002-05-28|Bacus Research Laboratories, Inc.|Method and apparatus for internet, intranet, and local viewing of virtual microscope slides|

---

US6272235B1|1997-03-03|2001-08-07|Bacus Research Laboratories, Inc.|Method and apparatus for creating a virtual microscope slide|

---

US6043880A|1997-09-15|2000-03-28|Becton Dickinson And Company|Automated optical reader for nucleic acid assays|

---

EP1023603B1|1997-10-07|2005-06-01|Ucb S.A.|Test device and method for determining analytes in a liquid dairy product|

---

US6041246A|1997-10-14|2000-03-21|Transonic Systems, Inc.|Single light sensor optical probe for monitoring blood parameters and cardiovascular measurements|

---

SE9703780D0|1997-10-17|1997-10-17|Tms Chem Ab|Capillary based immunoassay|

---

US6064474A|1998-02-06|2000-05-16|Optical Sensors, Inc.|Optical measurement of blood hematocrit incorporating a self-calibration algorithm|

---

US6235536B1|1998-03-07|2001-05-22|Robert A. Levine|Analysis of quiescent anticoagulated whole blood samples|

---

US6350613B1|1998-03-07|2002-02-26|Belton Dickinson & Co.|Determination of white blood cell differential and reticulocyte counts|

---

US6929953B1|1998-03-07|2005-08-16|Robert A. Levine|Apparatus for analyzing biologic fluids|

---

US6723290B1|1998-03-07|2004-04-20|Levine Robert A|Container for holding biologic fluid for analysis|

---

JP4350897B2|1998-03-11|2009-10-21|ボーリンガーインゲルハイムミクロパルツゲーエムベーハー|Sample carrier|

---

US6181418B1|1998-03-12|2001-01-30|Gretag Macbeth Llc|Concentric spectrometer|

---

DE19820861B4|1998-05-09|2004-09-16|Bruker Axs Gmbh|Simultaneous X-ray fluorescence spectrometer|

---

US6094592A|1998-05-26|2000-07-25|Nellcor Puritan Bennett, Inc.|Methods and apparatus for estimating a physiological parameter using transforms|

---

US6064897A|1998-06-01|2000-05-16|Abbott Laboratories|Sensor utilizing Raman spectroscopy for non-invasive monitoring of analytes in biological fluid and method of use|

---

JP3437094B2|1998-07-03|2003-08-18|松下電器産業株式会社|Multi-wavelength fluorescence polarization method|

---

US6214629B1|1998-08-06|2001-04-10|Spectral Diagnostics, Inc.|Analytical test device and method for use in medical diagnoses|

---

US6410341B1|1998-08-06|2002-06-25|Spectral Diagnostics, Inc.|Analytical test device and method for use in medical diagnoses|

---

US6087182A|1998-08-27|2000-07-11|Abbott Laboratories|Reagentless analysis of biological samples|

---

DE19840731A1|1998-09-07|2000-03-09|Hoechst Marion Roussel De Gmbh|Two-color differential display as a method for the detection of regulated genes|

---

US6154282A|1998-10-26|2000-11-28|Cytotelesis Inc.|Semiconductor based excitation illuminator for fluorescence and phosphorescence microscopy|

---

WO2000028297A2|1998-11-05|2000-05-18|Chemometec A/S|A method for the assessment of particles and a system and a device for use in the method|

---

WO2000029847A2|1998-11-16|2000-05-25|Umedik, Inc.|Device and method for analyzing a biologic sample|

---

US6187592B1|1998-12-23|2001-02-13|Sandia Corporation|Method for determining properties of red blood cells|

---

DE60044490D1|1999-02-23|2010-07-15|Caliper Life Sciences Inc|MANIPULATION OF MICROTEILS IN MICROFLUID SYSTEMS|

---

US6305804B1|1999-03-25|2001-10-23|Fovioptics, Inc.|Non-invasive measurement of blood component using retinal imaging|

---

EP1040788B1|1999-03-29|2001-12-19|F.Hoffmann-La Roche Ag|Apparatus for quantitative determination of the local distribution of a measurement value|

---

US6453060B1|1999-06-29|2002-09-17|Tri Path Imaging, Inc.|Method and apparatus for deriving separate images from multiple chromogens in a branched image analysis system|

---

US6284142B1|1999-09-03|2001-09-04|Baxter International Inc.|Sensing systems and methods for differentiating between different cellular blood species during extracorporeal blood separation or processing|

---

US6294094B1|1999-09-03|2001-09-25|Baxter International Inc.|Systems and methods for sensing red blood cell hematocrit|

---

US6611320B1|1999-09-08|2003-08-26|Optoq Ab|Method and apparatus|

---

JP2001088098A|1999-09-14|2001-04-03|Kawamura Inst Of Chem Res|Micro chemical device with depressurized liquid feeding mechanism|

---

US6696240B1|1999-10-26|2004-02-24|Micronix, Inc.|Capillary test strip to separate particulates|

---

US6665060B1|1999-10-29|2003-12-16|Cytyc Corporation|Cytological imaging system and method|

---

US6825921B1|1999-11-10|2004-11-30|Molecular Devices Corporation|Multi-mode light detection system|

---

US6563585B1|1999-11-24|2003-05-13|University Of Maryland Biotechnology Institute|Ratiometric fluorometer|

---

JP2001221951A|1999-11-29|2001-08-17|Olympus Optical Co Ltd|Microscope|

---

US6716588B2|1999-12-09|2004-04-06|Cellomics, Inc.|System for cell-based screening|

---

US6612111B1|2000-03-27|2003-09-02|Lifescan, Inc.|Method and device for sampling and analyzing interstitial fluid and whole blood samples|

---

SE518539C2|2000-06-28|2002-10-22|Migrata U K Ltd|Method and cuvette for quantitative hemoglobin determination in undiluted whole blood|

---

US6858400B2|2000-07-05|2005-02-22|Cynthia L Bristow|Detection of surface-associated human leukocyte elastase|

---

DE10033268C2|2000-07-10|2002-08-08|Innovatis Gmbh|Method for examining cells in a culture fluid|

---

US7630063B2|2000-08-02|2009-12-08|Honeywell International Inc.|Miniaturized cytometer for detecting multiple species in a sample|

---

US7139073B1|2000-09-04|2006-11-21|Hamamatsu Photonics K.K.|Imaging apparatus|

---

US20020187485A1|2000-10-25|2002-12-12|Jakobsen Mogens Hausteen|Open substrate platforms suitable for analysis of biomolecules|

---

GB0029154D0|2000-11-30|2001-01-17|Lee Helen|Signal enhancement with multiple labelled-antibodies|

---

US6826424B1|2000-12-19|2004-11-30|Haishan Zeng|Methods and apparatus for fluorescence and reflectance imaging and spectroscopy and for contemporaneous measurements of electromagnetic radiation with multiple measuring devices|

---

AT364174T|2001-01-26|2007-06-15|Biocal Technology Inc|OPTICAL DETECTION IN A MULTI-CHANNEL BIOSEPARATION SYSTEM|

---

US6960165B2|2001-05-16|2005-11-01|Olympus Corporation|Endoscope with a single image pick-up element for fluorescent and normal-light images|

---

US7531362B2|2001-06-07|2009-05-12|Medmira Inc.|Rapid diagnostic assay|

---

EP1405073B1|2001-07-11|2010-03-03|National Health Laboratory Service|Cell enumeration|

---

WO2003014678A1|2001-08-10|2003-02-20|Gbc Scientific Equipment Pty Ltd|Atomic absorption spectrometer|

---

ES2430854T3|2001-09-06|2013-11-22|Rapid Micro Biosystems, Inc.|Rapid detection of cells in replication|

---

US6862534B2|2001-12-14|2005-03-01|Optiscan Biomedical Corporation|Method of determining an analyte concentration in a sample from an absorption spectrum|

---

SE0104443D0|2001-12-28|2001-12-28|Hemocue Ab|Analysis method and cuvette for that|

---

EP1474772A4|2002-02-14|2005-11-09|Immunivest Corp|Methods and algorithms for cell enumeration in a low-cost cytometer|

---

US20040224329A1|2003-05-08|2004-11-11|Gjerde Douglas T.|Three-dimensional solid phase extraction surfaces|

---

WO2004100887A2|2003-05-08|2004-11-25|Phynexus, Inc.|Three-dimensional solid phase extraction surfaces|

---

US20030230728A1|2002-06-13|2003-12-18|Zhengshan Dai|Multiwavelength transilluminator for absorbance and fluorescence detection using light emitting diodes|

---

JP3869324B2|2002-06-26|2007-01-17|オリンパス株式会社|Image processing device for fluorescence observation|

---

WO2004017374A2|2002-08-16|2004-02-26|Clinical Microarrays, Inc.|Reading of fluorescent arrays|

---

US7279134B2|2002-09-17|2007-10-09|Intel Corporation|Microfluidic devices with porous membranes for molecular sieving, metering, and separations|

---

US20040142484A1|2002-09-30|2004-07-22|Intel Corporation|Spectroscopic analysis system and method|

---

AU2003275940A1|2002-10-31|2004-05-25|Chemometec A/S|A method for assessment of particles|

---

US6985224B2|2003-03-14|2006-01-10|The United States Of America As Represented By The Secretary Of The Navy|Light emitting diode array for excitation emission matrix fluorescence spectroscopy|

---

US7271912B2|2003-04-15|2007-09-18|Optiscan Biomedical Corporation|Method of determining analyte concentration in a sample using infrared transmission data|

---

US6999173B2|2003-09-25|2006-02-14|Ffa Sciences Llc|Method and apparatus for ratio fluorometry|

---

US20050142565A1|2003-12-30|2005-06-30|Agency For Science, Technology And Research|Nucleic acid purification chip|

---

WO2005071372A1|2004-01-23|2005-08-04|Olympus Corporation|Image processing system and camera|

---

US7781226B2|2004-02-27|2010-08-24|The Board Of Regents Of The University Of Texas System|Particle on membrane assay system|

---

US7265669B2|2004-03-01|2007-09-04|Mesosystems Technology, Inc.|Networks with sensors for air safety and security|

---

WO2005090969A1|2004-03-18|2005-09-29|Fuji Photo Film Co., Ltd.|Analysis element for use in method of testing specimen|

---

US20050214737A1|2004-03-26|2005-09-29|Dejneka Matthew J|Transparent filtered capillaries|

---

ES2548567T3|2004-04-07|2015-10-19|Levine, Robert Aaron|Disposable chamber to analyze biological fluids|

---

US7674598B2|2004-05-21|2010-03-09|Beckman Coulter, Inc.|Method for a fully automated monoclonal antibody-based extended differential|

---

US7625712B2|2004-05-21|2009-12-01|Beckman Coulter, Inc.|Method for a fully automated monoclonal antibody-based extended differential|

---

JP2006006834A|2004-06-29|2006-01-12|Pentax Corp|Electronic endoscope system|

---

WO2006047831A1|2004-11-03|2006-05-11|Agen Biomedical Limited|Detection device and method|

---

DE102004063438A1|2004-12-23|2006-07-06|Oktavia Backes|Novel microfluidic sample carriers|

---

JP4566754B2|2005-01-12|2010-10-20|Ｈｏｙａ株式会社|Image processing device|

---

EP1851545B1|2005-02-25|2014-12-31|Dako Denmark A/S|Cell counting|

---

SE528697C2|2005-03-11|2007-01-30|Hemocue Ab|Volumetric determination of the number of white blood cells in a blood sample|

---

US20060241495A1|2005-03-23|2006-10-26|Eastman Kodak Company|Wound healing monitoring and treatment|

---

WO2007012975A1|2005-03-29|2007-02-01|Inverness Medical Switzerland Gmbh|Hybrid device|

---

EP2605020B1|2005-03-29|2017-05-17|Sysmex Corporation|Method of specimen analysis and specimen analyzer|

---

EP2453223B1|2005-04-12|2019-07-03|Caliper Life Sciences Inc.|Optical detection system for a microfluidic device and method for aligning and focusing an optical detection system|

---

US20070014695A1|2005-04-26|2007-01-18|Applera Corporation|Systems and Methods for Multiple Analyte Detection|

---

EP2312317A3|2005-05-03|2011-06-08|Life Technologies Corporation|Fluorescent detection system and dye set for use therewith|

---

EP1910824A4|2005-05-31|2012-11-21|Labnow Inc|Methods and compositions related to determination and use of white blood cell counts|

---

CA2610753C|2005-09-13|2014-04-29|Edwards Lifesciences Corporation|Continuous spectroscopic measurement of total hemoglobin|

---

DE102005052752A1|2005-11-04|2007-05-10|Clondiag Chip Technologies Gmbh|Apparatus and method for detecting molecular interactions|

---

US8353848B2|2005-11-21|2013-01-15|Alere Switzerland Gmbh|Test device|

---

JP4887989B2|2005-12-02|2012-02-29|ナノフォトン株式会社|Optical microscope and spectrum measuring method|

---

US7515268B1|2006-02-02|2009-04-07|E.I. Spectra, Llc|Fluorescence-activated cell detector|

---

SE531233C2|2006-03-28|2009-01-27|Hemocue Ab|Apparatus and method for detecting fluorescently labeled biological components|

---

US7790464B2|2006-05-04|2010-09-07|Blaze Medical Devices, LLC|Blood hemolysis analyzer|

---

SE530244C2|2006-05-05|2008-04-08|Hemocue Ab|Method and system for quantitative hemoglobin determination|

---

EP2041573B1|2006-06-23|2019-09-04|PerkinElmer Health Sciences, Inc.|Methods and devices for microfluidic point-of-care immunoassays|

---

SE530750C2|2006-07-19|2008-09-02|Hemocue Ab|A measuring device, a method and a computer program|

---

WO2008037068A1|2006-09-29|2008-04-03|Ottawa Health Research Institute|Correlation technique for analysis of clinical condition|

---

US7952692B2|2006-12-12|2011-05-31|Orsense Ltd.|Method and apparatus for determination of analyte concentration|

---

US8244021B2|2006-12-20|2012-08-14|Ventana Medical Systems, Inc.|Quantitative, multispectral image analysis of tissue specimens stained with quantum dots|

---

US7738094B2|2007-01-26|2010-06-15|Becton, Dickinson And Company|Method, system, and compositions for cell counting and analysis|

---

US20080213823A1|2007-02-23|2008-09-04|Christensen Kenneth A|Capillary-channeled polymer film flow cytometry|

---

US7518727B2|2007-02-28|2009-04-14|Beckman Coulter, Inc.|Multicapillary multilaser detection system|

---

EP2153208A1|2007-04-12|2010-02-17|Regents of the University of Minnesota|Systems and methods for analyzing a particulate|

---

EP1990638A1|2007-05-11|2008-11-12|Koninklijke Philips Electronics N.V.|Flow-through biosensor|

---

US7816135B2|2007-07-05|2010-10-19|Becton, Dickinson And Company|Method of analyzing lymphocytes|

---

US7927561B2|2008-01-10|2011-04-19|Becton, Dickinson And Company|Rapid particle detection assay|

---

SE532499C2|2008-01-18|2010-02-09|Hemocue Ab|Method and apparatus for analyzing particles in a liquid sample|

---

US7903241B2|2008-03-21|2011-03-08|Abbott Point Of Care, Inc.|Method and apparatus for determining red blood cell indices of a blood sample utilizing the intrinsic pigmentation of hemoglobin contained within the red blood cells|

---

US8306594B2|2008-06-12|2012-11-06|Paseman Sabrina K|Transmission fluorometer|

---

US9017946B2|2008-06-23|2015-04-28|Canon U.S. Life Sciences, Inc.|Systems and methods for monitoring the amplification of DNA|

---

WO2010019515A2|2008-08-10|2010-02-18|Board Of Regents, The University Of Texas System|Digital light processing hyperspectral imaging apparatus|

---

AU2010206657A1|2009-01-23|2011-08-11|Drexel University|Apparatus and methods for detecting inflammation using quantum dots|

---

US20100291599A1|2009-05-18|2010-11-18|Bruker Optics, Inc.|Large area scanning apparatus for analyte quantification by surface enhanced raman spectroscopy and method of use|

---

WO2011133540A2|2010-04-19|2011-10-27|Research Foundation Of State University Of New York|Capillary biosensor system and its method of use|

---

JP5462084B2|2010-06-21|2014-04-02|オリンパス株式会社|Image processing apparatus and program|

---

JP5092104B2|2010-08-30|2012-12-05|ナノフォトン株式会社|Spectrometer and spectroscopic method|

---

EP2780705B1|2011-11-16|2018-09-19|Becton, Dickinson and Company|Methods and systems for detecting an analyte in a sample|

---

CN104755925B|2013-01-11|2017-06-23|贝克顿·迪金森公司|The point-of-care of low cost determines device|

---

BR112016009958B1|2013-11-06|2021-08-03|Becton, Dickinson And Company|MICROFLUIDIC DEVICE, METHOD, SYSTEM AND KIT|

---

JP6518245B2|2013-11-13|2019-05-22|ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ|Optical imaging system and method using the same|EP2780705B1|2011-11-16|2018-09-19|Becton, Dickinson and Company|Methods and systems for detecting an analyte in a sample|

---

CN108267581A|2012-08-24|2018-07-10|耶鲁大学|For the systems, devices and methods of high-throughput multi detection|

---

CN104755925B|2013-01-11|2017-06-23|贝克顿·迪金森公司|The point-of-care of low cost determines device|

---

EP3060916B1|2013-10-22|2019-07-10|The Regents of The University of California|Microfluidic assay devices and methods for making and using the same|

---

BR112016009958B1|2013-11-06|2021-08-03|Becton, Dickinson And Company|MICROFLUIDIC DEVICE, METHOD, SYSTEM AND KIT|

---

JP6518245B2|2013-11-13|2019-05-22|ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ|Optical imaging system and method using the same|

---

CN103983749B|2014-03-25|2015-06-17|中国海洋大学|Capillary immunity-chromatography rapid detection method for parvalbumin in aquatic products|

---

EP3692914A1|2014-10-14|2020-08-12|Becton, Dickinson and Company|Blood sample management using open cell foam|

---

WO2016090148A1|2014-12-03|2016-06-09|IsoPlexis Corporation|Analysis and screening of cell secretion profiles|

---

CN106604780B|2015-03-10|2019-06-25|贝克顿·迪金森公司|The micro- sample management device of biofluid|

---

WO2017007791A1|2015-07-06|2017-01-12|Scinovia Corp.|Fluorescence based flow imaging and measurements|

---

CA2996863C|2015-09-01|2021-04-13|Becton, Dickinson And Company|Depth filtration device for separating specimen phases|

---

WO2017053839A1|2015-09-25|2017-03-30|Iontox, Llc|Endocrine disruptor field tester|

---

US10814319B2|2016-09-30|2020-10-27|Board Of Regents, University Of Texas System|Functionalized polyolefin capillaries for open tubular ion chromatography|

---

JP2020524806A|2017-06-12|2020-08-20|エッセンリックス コーポレーション|Homogeneous assay|

---

CN111801575A|2018-01-27|2020-10-20|贝克顿·迪金森公司|Multiple lateral flow assay to distinguish between bacterial and viral infections|

---

CN111936852A|2018-01-27|2020-11-13|贝克顿·迪金森公司|Multiple lateral flow assay to distinguish between bacterial and viral infections|

法律状态:
2018-03-27| B06F| Objections, documents and/or translations needed after an examination request according art. 34 industrial property law|

---

2019-08-13| B06U| Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure|

---

2020-09-15| B09A| Decision: intention to grant|

---

2020-12-22| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/11/2012, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US201161560752P| true| 2011-11-16|2011-11-16|

---

US61/560,752|2011-11-16|

---

PCT/US2012/065683|WO2013075031A1|2011-11-16|2012-11-16|Methods and systems for detecting an analyte in a sample|

---